SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934.
For the fiscal year ended September 30, 2002.
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934. For the transition period from -------- to--------
Commission File Number: 001-10382
VALLEY FORGE SCIENTIFIC CORP.
(Exact name of registrant as specified in its charter)
PENNSYLVANIA 23-2131580
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification no.)
136 Green Tree Road, Oaks, Pennsylvania 19456
(Address of principal executive offices and zip code)
Telephone: (610) 666-7500
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Name of Each Exchange
Title of Each Class on which Registered
------------------- ---------------------
Common Stock, no par value Boston Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No[ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [X]
Indicate by check mark whether the Registrant is an accelerated filer (as
defined in Exchange Act Rule 12b-2).
Yes [ ] No [X]
The aggregate market value of voting stock held by non-affiliates of the
registrant, computed by reference to the closing bid and ask prices as reported
by the Nasdaq system on December 13, 2002 was $6,336,774.
At December 13, 2002 there were 8,024,312 shares of the Registrant's Common
Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Certain information required by Items 10, 11, 12 and 13 of Form 10-K is
incorporated by reference from the Definitive Proxy Statement for the Annual
Meeting of Stockholders of the Registrant, or an Amendment to this Annual Report
on Form 10-K, to be filed within 120 days after the end of the fiscal year
covered by this Annual Report on Form 10-K.
VALLEY FORGE SCIENTIFIC CORP.
FORM 10-K
FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2002
TABLE OF CONTENTS
PART I
PAGE
----
Item 1. Business 1
Item 2. Properties 16
Item 3. Legal Proceedings 16
Item 4. Submission of Matters to a Vote of Security Holders 16
PART II
Item 5. Market for Registrant's Common Equity and Related Stock
holder Matters 16
Item 6. Selected Financial Data 17
Item 7. Management's Discussion and Analysis of Financial Condition
and Results of Operation 17
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 26
Item 8. Financial Statements and Supplementary Data 26
Item 9. Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure 26
PART III
Item 10. Directors and Executive Officers of the Registrant 26
Item 11. Executive Compensation 26
Item 12. Security Ownership of Certain Beneficial Owners and
Management and Related Stockholder Matters 26
Item 13. Certain Relationships and Related Transactions 26
PART IV
Item 14. Controls and Procedures 26
Item 15. Exhibits, Financial Statement Schedules and Reports
on Form 8-K 27
Bident(R) is our registered trademark and DualWave(TM) is our trade name.
MALIS(R) is the trademark of Dr. Leonard I. Malis. All other trademarks or trade
names referred to in this Report are the property of their respective owners.
(i)
VALLEY FORGE SCIENTIFIC CORP.
PART I
------
Item 1. BUSINESS
--------
This report on Form 10-K contains certain forward looking statements
regarding future events with respect to Valley Forge Scientific Corp. ("Valley
Forge Scientific", "we", "us" and "our" refer to Valley Forge Scientific Corp.,
a Pennsylvania corporation, unless the context otherwise requires). Actual
events or results could differ materially due to a number of factors, including,
those described herein and in the documents incorporated herein by reference and
those factors described under the headings "Forward Looking Statements."
Nature of Our Business
Valley Forge Scientific, which was incorporated on March 27, 1980,designs,
develops, manufactures and sells medical devices. Our core business is in our
bipolar electrosurgical generators and related instrumentation, based on our
DualWave(TM) technology. Our DualWave(TM) technology involves the use of two
waveforms, one to perform bipolar cutting of tissue and the other to perform
bipolar coagulation, or sealing, of blood vessels. Our bipolar systems are
designed to replace other surgical tools, such as monopolar systems, lasers and
conventional scalpels used in soft tissue surgery.
All electrosurgical units utilize handheld instruments to deliver the
current from the generator to the patient's tissue. Traditional monopolar
instruments have a single, monopolar, electrode tip that advances a spark
between the electrode tip and the tissue. The electrical current generated is
attracted to a grounding pad attached to the patient's thigh or buttock and
electrical current and heat are diffused to tissues between the surgical site
and the site of the grounding pad. This can result in heat damage, charring and
unpredictable/prolonged healing in the surgical area, as well as collateral
damage to tissues along the electrical pathway to the grounding pad. The
monopolar method of cutting and coagulation is also rendered obsolete in
delicate areas of the human body, specifically the brain and spine, due to the
inability to control current and heat spread.
Bipolar electrosurgery is descriptive of the means of current delivery to
the patient. Bipolar electrosurgery employs a unique delivery system to overcome
the safety hazards associated with the grounding pad in monopolar
electrosurgery. In bipolar electrosurgery a handheld instrument with two
electrodes is used to deliver the current to soft tissue and blood vessels. The
electrodes are closely juxtaposed, so that current flows only between the
electrodes, affecting only the tissue or blood vessel between the electrodes.
Current is confined to the immediate surgical site so that no grounding pad is
required and peripheral tissue damage is virtually eliminated.
Our bipolar electrosurgery system, provides the surgeon one waveform to
safely and precisely cut, core and divide tissue and another waveform to provide
a gentle and precise coagulation. Our cutting waveform uses molecular resonance
to cut, instead of heat through an advancing spark, which is used in monopolar
systems. With the virtual elimination of heat and current spread, our technology
can be used anywhere in the human body safely, specifically the
[1]
brain and spine. Our unique coagulation waveform uses a totally aperiodic and
non-rhythmic waveform, eliminating the molecular resonance and the possibility
of inadvertently cutting tissue when the surgeon intends to coagulate. These
precise and differentiated waveforms allow surgeons to work in direct contact
with nerves, blood vessels, bone and metal implants without the inherent dangers
associated with other methods of electrosurgery.
Our bipolar systems consist of a solid state microprocessor controlled
generator, utilizing our DualWave(TM) bipolar circuitry technology, an array of
disposable hand-held instruments to perform a variety of surgical procedures,
single-use disposable cords which attach the hand-held bipolar instrument to the
generator and other modules and accessories.
We do not market or sell our products directly to the end users. Our
neurosurgery bipolar systems, which are used by neurosurgeons worldwide, are
marketed by Codman & Shurtleff, Inc., a subsidiary of Johnson & Johnson, Inc.
Our Bident(R) bipolar dental system is marketed by Bident International, L.L.C.
pursuant to a distribution agreement. We have recently decided to change the
marketing plan for our dental products and are in the process of terminating our
distribution agreement with Bident International, LLC. Our new marketing plan
focuses on direct marketing and sales of our Bident(R) bipolar dental system to
national dental product dealers. We believe this plan will achieve greater
market penetration of our products in the dental market.
Our strategy is to expand our product offerings in neurosurgery, increase
sales of our Bident(R) bipolar dental system by directly selling our products to
an expanded based of national dental product dealers and broaden the market for
our products in other clinical and surgical markets that have a need for bipolar
electrosurgery. Our strategy also includes using our DualWave(TM) technology and
sales of our bipolar generators to drive sales of complementary disposable
hand-held instruments and products.
Our neurosurgery bipolar systems, which were first introduced into the
market by Codman & Shurtleff in 1983, account for a significant amount of our
sales.
We have 510(k) clearance to market our bipolar electrosurgical generators
and disposable instrumentation, based on our DualWave(TM) technology, from the
United States Food and Drug Administration, the FDA. Our Bident(R) bipolar
dental system has also been granted 510(k) clearance to market by the FDA. Our
neurosurgery bipolar system is CE marked, which is a requirement to sell the
product in most of Western Europe.
To complement the sales of our bipolar systems, we also manufacture for
sale titanium surgical mesh for repair of the skull and a natural dental
preparation for use in healing and lessening post surgical discomfort. As
markets for our bipolar systems expand, we may manufacture and sell other
complementary products.
Our Business Strategy
Our objective is to expand upon the success of our DualWave(TM) technology
in neurosurgery and to broaden the market for our bipolar systems and bipolar
instrumentation in the dental market and other clinical and surgical markets.
Our strategies to achieve this goal are as follows:
[2]
Expansion of Our Product Base. We plan to continue to aggressively proceed
in the development of additional products based on our DualWave(TM) technology
and develop new technologies to satisfy the needs of the medical community. By
working with leading practitioners in their fields, we look to refine existing
features and develop new features, enhancements and new instrumentation to
provide surgeons with more functionality.
Expansion of the Use of Our Bipolar(R) Systems Based on Our DualWave(TM)
Technology. Building upon our DualWave(TM) technology and its use in
neurosurgery and the dental market, we continue to research market potential and
product refinement opportunities for additional clinical applications of our
DualWave(TM) technology. Potential fields include: general surgery, minimally
invasive applications in various clinical fields, maxillofacial surgery, ENT,
plastic surgery and other intracranial applications.
Use Our Generators to Drive Disposable Product Sales. The sales of our
disposable hand-held instruments and disposable tubing sets are influenced by
three factors: the increased installed base of our bipolar generators, the
increased product offerings of disposables and physician acceptance of our
products. As new types of disposable hand-held instruments are introduced into
the neurosurgery market and as more bipolar generators are sold in the dental
market and other clinical markets, we expect sales of complementary disposable
hand-held instruments and cord and tubing sets to increase.
Continue to Establish Strategic Distribution Relationships to Commercialize
Our Product Offerings. We enter into distribution contracts with third party
companies to market our products to end-users. In neurosurgery, we have chosen
to contract with Codman & Shurtleff, Inc., a subsidiary of Johnson & Johnson,
Inc., to market and distribute our products. In the dental market we recently
decided to change our marketing plan, and we are now establishing direct
marketing relationships with national dental product dealers to sell our
Bident(R) bipolar dental system. In September 2002, we entered into a
development agreement with Stryker Corporation for a new product for use in a
field outside of the neurosurgery and dental fields.
In neurosurgery, there are numerous published clinical reports and
follow-up studies on the use of our system, which support the marketing efforts
of our neurosurgery bipolar systems. In dentistry, leading practitioners have
written numerous articles and clinical reports supporting the use of our system.
We intend to utilize the reports and studies currently published for marketing
in other fields, however, we will need continued recommendations and
endorsements by influential surgeons for market acceptance of our bipolar
systems in fields other than neurosurgery and for market acceptance of our
disposable hand-held instruments and other new product offerings in the field of
neurosurgery.
Electrosurgery
Surgical procedures are performed using a variety of methods and
instruments, including electrosurgical generators. Electrosurgical generators
perform two specific functions, tissue cutting and coagulation (sealing) of
blood vessels.
[3]
The application of hot cautery to seal blood vessels has been in existence
for more than 5,000 years. Early cauterization techniques employed iron
instruments heated in an open flame, then introduced into the wound. The
electrosurgical generator was first introduced in 1924, by noted neurosurgeon,
Dr. Harvey Cushing, who partnered with a Harvard University physicist, Dr.
William Bovie, to design a spark gap electrosurgical generator. The generator
worked by advancing a spark to tissue, to generate heat, providing
cauterization.
Today's electrosurgical generators have become more sophisticated,
utilizing radiofrequency, or RF, waves to cut and coagulate tissue. Modern
electrosurgical generators are distinguished as either "monopolar" or "bipolar".
The classification refers to the method by which electricity is delivered to the
patient and returned to the generator. Fundamental electrical principles apply.
Electricity must complete a circle. It must have a beginning point, a return
path, and an ending point.
Monopolar Electrosurgical Systems
In monopolar electrosurgery, a single RF sine wave is created in the
generator to provide cutting and coagulation. Connected to the generator is an
insulated, hand held instrument with only one tip. This is the "active
electrode". The return path of this applied electricity is through the patient's
body, to a grounding pad attached to the patient's body, usually the thigh or
buttocks, which returns the electricity to the generator, completing the
circuit. Traditional monopolar electrosurgical cutting uses high temperature
heat to burn away targeted tissue. This typically results in thermal (heat)
damage, charring and unpredictable/prolonged healing in the surgical area.
Monopolar cutting does not work well in a wet field due to short circuiting,
which exacerbates tissue damage due to heat and dryness.
There are three significant safety hazards recognized with
the monopolar system:
* There is considerable heat buildup at the surgical site;
* The electricity must travel through the patient's body to
reach the grounding pad, damaging healthy blood vessels and tissue
along its path; and
* The patient can be burned by the electricity leaving the body at the
site of the grounding pad.
Monopolar units do not provide a separate waveform or delivery system for
coagulation. The surgeon changes the angle of the instrument touching tissue,
using the heat buildup of the instrument itself to coagulate tissue.
Bipolar Electrosurgical Systems
Bipolar electrosurgery is descriptive of the means of current delivery to
the patient. In bipolar systems, the RF sine wave is generated, and delivered to
the surgical site via a handheld instrument that provides the "active" and
"return" electrodes. The electricity generated is applied only to the tissue
between the two electrodes of the instrument. The electricity is returned to the
generator through the instrument, removing the patient from the electrical
circuit and eliminating not only the need for a grounding pad, but the inherent
safety hazards associated with monopolar electrosurgery.
[4]
We believe that the use of only one waveform to perform both functions
of cutting and coagulation is not as safe as using one waveform for coagulation
and another waveform for cutting, such as provided by our Dualwave(TM)
generators. By using one waveform, there is always the potential to cut when the
surgeon is trying to coagulate, and thus perforate blood vessels inadvertently.
Our DualWave(TM) bipolar electrosurgical generators use two waveforms to perform
the two separate and distinct functions of cutting and coagulation.
Valley Forge Scientific Technology
The foundation of our bipolar electrosurgical systems lies in our
DualWave(TM) technology. Using our DualWave(TM) technology, our bipolar
generators are able to deliver two separate waveforms to perform the two
separate and distinct functions of cutting and coagulation.
We do not believe that it is either safe or effective to use the same
waveform for coagulation that is used for cutting. With the virtual elimination
of heat and current spread, our technology can be used in direct contact with
nerves, bones, blood vessels and metal implants, and can be used anywhere in the
human body safely, specifically the brain and spine.
Our bipolar systems consist of a solid state microprocessor controlled
generator, utilizing our DualWave(TM) technology, an array of disposable
hand-held bipolar instruments, which perform a variety of surgical and dental
procedures, and single-use disposable cords, which attach the hand-held bipolar
instrument to the generator. We also develop, manufacture and sell modules and
other accessories to handle specific functions required by a particular
surgical discipline. For example, in neurosurgery we sell an irrigation module,
which allows the neurosurgeon to pump a saline solution into the surgical field
while cutting tissue or coagulating blood vessels, and a specially designed
single-use plastic tube set, which connects the electrical current from the
generator and fluid from the irrigation module to the hand-held instrument.
Our cutting waveform uses molecular resonance to cut, rather than heat
through an advancing spark. Our generator contains a rigidly stabilized voltage
control to provide an extremely gentle cut, using about one fifth the power of
other generators. The cutting current, which is delivered only to the tissue
between the two electrodes of the instrument, offers safety advantages by the
absence of current spread and markedly reduced heating of adjacent tissues. This
makes our product safe to use in all areas of the human body, specifically in
the most sensitive areas, the brain and the spine.
Our coagulation waveform is unique in that it is totally aperiodic and
nonrhythmic. The timing of electrical bursts within the waveform are randomly
spaced, and the waveform itself is random in timing so that it is truly
aperiodic. Regardless of how high the voltage setting of the unit, or how long
the surgeon applies the current, the coagulation waveform simply will not cut.
Our strictly regulated constant voltage supply allows for precise, gentle and
progressive coagulation in either totally dry or fully irrigated fields,
including fields totally submerged in saline. These effects are produced in our
generators through the lowest possible output impedance.
Our bipolar electrosurgical generators deliver both cutting and coagulation
through bipolar handheld instruments, providing both the active electrode and
the return path through the handheld instrument back to the generator. The
performance of our bipolar disposable handheld instruments is also enhanced by
an irrigated field, further minimizing the risk of heat buildup and correlating
tissue damage. Our bipolar systems are designed to replace other surgical tools,
such as monopolar electrosurgical systems, lasers and conventional instruments,
such as scalpels, used in soft tissue surgery.
[5]
We believe that our bipolar systems, using our DualWave(TM) technology,
can be used in all procedures involving cutting tissue or coagulating blood
vessels throughout the human body.
Our neurosurgery bipolar systems, which were first introduced into the
market by Codman & Shurtleff in 1983, account for a significant amount of our
sales. To date, a total of seven neurosurgical disposable hand-held instruments
utilizing our DualWave(TM) technology have been developed. We are discussing
with Codman & Shurtleff, Inc. refining and expanding our disposable instrument
product offering for re-introduction in 2003.
Our Bident(R) bipolar dental system was introduced into the dental market
by Bident International, L.L.C. in 1999. We have recently decided to change the
marketing plan for our dental products and are in the process of terminating our
distribution agreement with Bident International, LLC. Our new marketing plan
focuses on direct marketing and sales of our Bident(R) bipolar dental system to
national dental product dealers. We feel that this marketing plan will achieve
greater market penetration of our products in the dental market. We are in the
early stages of establishing the infrastructure to support our dental dealer
marketing effort and we have planned a marketing campaign for the first half of
calendar 2003 targeting dentists, periodontists and oral surgeons, with a direct
consumer approach.
The Neurosurgery Market
There are more than 3,600 Board Certified Neurological Surgeons,
neurosurgeons, in the United States, and more than 5,800 worldwide. Neurological
surgery is a medical specialty dealing with disorders of the brain, skull,
spinal cord, cranial and spinal nerves, the autonomic nervous system and the
pituitary gland. It is believed that approximately 500,000 brain and spine
surgery procedures are performed each year in the United States. The American
Academy of Neurological Surgeon has published a survey of United States
procedural statistics for 1999. In that survey, it is reported that
approximately 533,000 spine procedures and 220,000 cranial procedures were
performed in 1999.
A prominent use of bipolar electrosurgical instrumentation in neurosurgery
is tumor removal. There are over 100 different types of brain tumors. More than
180,000 Americans are diagnosed with brain tumors each year. The most common
brain tumors in adults are: glioblastoma, meningioma, and oligodendroglioma.
Approximately 2,200 children are diagnosed with a brain tumor each year, with
the most common being medulloblastoma and astrocytoma. The first line of
treatment for these tumors is typically surgical removal of the tumor.
For each bipolar neurosurgical procedure, the neurosurgeon needs a
hand-held instrument that will cut, divide, core or remove tissue and tumors and
coagulate blood vessels. The neurosurgeon also needs to connect that instrument
with a cord/tubing set to the bipolar generator and irrigation unit, which
provides fluids to the surgical site. This area of practice demands that the
cord/tubing sets be single-use. We believe that as neurosurgeons are educated on
the functionality and cost advantages of our disposable neurosurgical hand-held
instruments, our sales of these instruments will increase.
[6]
In neurosurgery, a bipolar electrosurgical system is the modality of
choice, largely due to the efforts of Dr. Leonard I. Malis, one of our
directors. Dr. Malis, who is Professor and Chairman Emeritus of the Mount Sinai
School of Medicine Department of Neurosurgery, designed and developed the first
commercial bipolar coagulator in 1955, and pioneered the use of bipolar
electrosurgery for use in the brain. Dr. Malis is a frequent author and lecturer
on neurosurgery and bipolar electrosurgery.
Our Neurosurgery Bipolar Systems.
- --------------------------------
Our neurosurgery bipolar systems, which were developed in conjunction with
Dr. Malis, are used to cut, core and divide tissue and tumors and coagulate
blood vessels in the brain and spine. Our neurosurgery bipolar systems, which
are marketed and sold by Codman & Shurtleff, Inc. to end users under the
MALIS(R) tradename, are used by neurosurgeons worldwide.
Our neurosurgery bipolar system is a surgical device intended to perform
two separate functions: bipolar cutting of tissue and bipolar coagulation of
blood vessels. Our system is comprised of the bipolar electrosurgical generator,
an irrigation module, foot pedal, connecting cables, and an array of disposable
bipolar hand-held instrumentation in varying sizes and shapes connected to the
generator via a single-use disposable bipolar cord and tubing set.
Our bipolar generator delivers our DualWave(TM) bipolar cutting and bipolar
coagulation through radio frequency waveforms. Our irrigation modules deliver
fluids, such as saline, to the surgical field through a hand-held instrument.
Surgeons can use our disposable bipolar hand-held instruments to cut tissue and
to seal blood vessels in an irrigated surgical field. The surgeon can control
the mode of operation with the foot pedal and power setting with keys on the
front panel of the controller.
Our disposable bipolar hand-held instruments are approved for sale in
various tip sizes and shapes. We have developed seven different models of
disposable hand-held instruments for neurosurgery, which provide the surgeon
control and precision for different procedures during surgery. We believe that
the typical use per surgical procedure is one to two disposable instruments and
one disposable cord/tubing set.
Our current neurosurgery products consist of the following:
Generators/Irrigators
---------------------
* MALIS(R) CMC-III Bipolar Generator (High power cutting/coagulation)
* MALIS(R) Bipolar Synergy Generator (Low power coagulation)
* MALIS(R) Irrigation Module
Disposable Instrumentation and Cord sets
----------------------------------------
* MALIS(R) Bipolar Cutting Loops - 3x5mm
* MALIS(R) Bipolar Cutting Loops - 5x5mm
* MALIS(R) Bipolar Cutting Loops - 5x10mm
* MALIS(R) Bipolar Cutting Loops - 10x10mm
* MALIS(R) Bipolar Cutting Pen
* MALIS(R) Bipolar Coagulation Ball - 3mm
* MALIS(R) Bipolar Coagulation Ball - 5mm
* MALIS(R) Bipolar Cord/Irrigation Tubing Set
* MALIS(R) Bipolar Cord
[7]
The Dental Market
There are an estimated 150,000 professionally active dentists in the United
States. As primary oral health care providers, approximately 80% of dentists are
generalists, and approximately 20% are specialists. More than 90% of active
dentists are in private practice. There are approximately 55 dental schools in
the U.S. and Canada, and in 1999, there were over 17,000 students enrolled in
U.S. dental schools.
There are currently more than 20 different bipolar electrosurgical
procedures with American Dental Association, ADA, codes eligible for insurance
reimbursement. Examples of commonly performed procedures include:
* Gingivectomey / Gingivoplasty (surgical treatment of gingivitis),
* Connective tissue graft,
* Surgical removal of residual tooth roots,
* Crown and bridge preparation,
* Biopsy of oral tissue,
* Excision of cysts or tumors, benign and malignant, and
* Surgical removal of impacted or erupted tooth.
Our Bident(R) Bipolar Dental System
- -----------------------------------
Our Bident(R) bipolar dental system uses the same DualWave(TM) technology
used in our neurosurgery bipolar systems to allow dentists to work in direct
contact with metal implants, nerves, bone and blood vessels, essentially
eliminating collateral tissue damage from current spread and heat buildup. Our
Bident(R) bipolar dental system is marketed by Bident International, L.L.C.
pursuant to a distribution agreement. We have recently decided to change the
marketing plan for our dental products and are in the process of terminating our
distribution agreement with Bident International, LLC. Our new marketing plan
focuses on direct marketing and sales of our Bident(R) bipolar dental system to
national dental product dealers.
Dentists,similar to neurosurgeons, are particularly affected by the
limitations of monopolar electrosurgical systems to work safely around metal
implants, bone, nerves and blood vessels due to the nature of delicate
structures they work within. We believe, the elimination of the grounding pad
through bipolar delivery of our current to cut and coagulate in our Bident(R)
bipolar dental system is also an important factor to dentists concerned with
both safety, and patient perception/fear of the equipment used in the general
dentistry setting.
[8]
Our Bident(R) bipolar dental system is a surgical device, which performs
two separate functions: bipolar tissue cutting and bipolar coagulation of blood
vessels. The size, features and overall power output of the generator itself is
different than our neurosurgery bipolar system, to meet the need for a cost
effective, office style generator for the dentist. The system is comprised of
the electrosurgical generator, foot pedal, connecting cables and an array of
disposable bipolar hand-held instruments, which are attached to the generator
via a single use bipolar cord.
Dentists can use our disposable bipolar hand-held instruments to cut tissue
and to seal blood vessels in an irrigated surgical field. The dentist can
control the mode of operation with the foot pedal and power setting with keys on
the front panel of the generator.
Our disposable bipolar hand-held instruments are available in various tip
sizes, shapes and angles to perform the varying procedures performed by the
dentist. We currently sell sixteen different models of disposable bipolar
hand-held instruments for dental procedures. We believe that the typical use for
each dental surgical procedure is one to two disposable instruments and one
disposable cord set.
Our current bipolar dental products consist of the following:
Generator
---------
* Bident Bipolar Surgical System
Bipolar Instrument and Cord Sets
--------------------------------
* Bipolar Flap Access Pen
* Bipolar Gingivoplasty Pen
* Bipolar Gingivectomy Pen
* Bipolar Gingival Troughing Pen 5 mm (.012")
* Bipolar Gingivectomy Pen (.020")
* Bipolar Coagulating Ball 3mm
* Bipolar Coagulating Ball 3mm (30 degrees)
* Bipolar Gingivoplasty Loop 1.5x9mm
* Bipolar Gingivoplasty Loop 1.5x9mm (30 degrees)
* Bipolar Gingivoplasty Loop 3x5mm
* Bipolar Gingivoplasty Loop 3x5mm (30 degrees)
* Bipolar Gingivoplasty Loop 3x8mm
* Bipolar Gingivoplasty Loop 3x8mm (30 degrees)
* Bipolar Gingivoplasty Loop 5x5mm
* Bipolar Gingivoplasty Loop 5x5mm (30 degrees)
* Bipolar Cord Set
Other Surgical Markets
Building upon our DualWave(TM) technology and its use in neurosurgery, our
strategy is to expand the market for our bipolar systems and disposable bipolar
products in other clinical and surgical markets that have a need for bipolar
electrosurgery. We continue to research market potential and product refinement
opportunities for additional clinical applications of our DualWave(TM)
technology. Potential fields include: general surgery, minimally invasive
applications in various clinical fields, maxillofacial surgery, ENT, plastic
surgery and other intracranial applications. As we open new markets, we plan to
select national/international leading medical sales organizations specializing
in the applicable field(s) to launch our bipolar systems in the market place.
[9]
Manufacturing and Supplies
The manufacturing of our bipolar generators and irrigation systems have
been conducted by our wholly-owned subsidiary, Diversified Electronics Company,
Inc., in Philadelphia, Pennsylvania. Effective October 1, 2002, the operations
of Diversified Electronics Company, Inc. were merged with Valley Forge
Scientific's operations. Our products are manufactured from several components,
most of which are supplied to us by third parties. Most of the components we use
in the manufacture of our products are available from more than one supplier.
For some components, however, there are relatively few alternate sources of
supply and we rely upon single source suppliers or contract manufacturers. For
example, we currently subcontract the manufacturing of our disposable
instruments with a single contract manufacturer and we subcontract the
manufacture of our disposable cord and tube sets with a single manufacturer. Our
profit margins and our ability to develop and deliver such products on a timely
basis may be adversely affected by the lack of alternative sources of supply.
Our manufacturing process is subject to the regulatory requirements of the
Federal Good Manufacturing Practice Regulations as promulgated by the FDA, which
mandate detailed quality assurance and record-keeping procedures and subjects us
to unscheduled periodic regulatory inspections. We conduct quality assurance
audits throughout the manufacturing process and believe that we are in
compliance with all applicable government regulations.
Marketing and Sales
We do not directly market or sell our products to end-users. Instead, we
sell almost all of our products to or through national/international
distributors.
Codman & Shurtleff, Inc. For almost twenty years, we have entered into
distribution agreements with Codman & Shurtleff, Inc. to sell and distribute our
products in the field of neurosurgery. On December 11, 2000, we entered into a
new distribution agreement with Codman & Shurtleff, Inc. under which Codman &
Shurtleff, Inc. was granted the exclusive worldwide right to sell our bipolar
neurosurgery system and certain other products in the fields of neurocranial and
neurospinal surgery through December 31, 2003 on the condition that Codman &
Shurtleff, Inc. makes minimum purchases of $4,000,000 per calendar year, as may
be adjusted by mutual agreement of the parties. If Codman & Shurtleff, Inc.
fails to satisfy the minimum purchase obligations, our remedy is to terminate
the agreement or convert it to a nonexclusive agreement. We primarily perform
product development, manufacturing and clinical and regulatory functions for our
neurosurgery bipolar systems.
For the 2002, 2001 and 2000 fiscal years, we had sales to Codman &
Shurtleff, Inc. of approximately $4,515,000, $4,169,000 and $3,696,000,
respectively. Orders are generally filled on a current basis in each calendar
year. Approximately 90% of our sales revenue was derived from sales to Codman &
Shurtleff, Inc. in fiscal 2002 and approximately 79% and 84% of our sales were
derived from sales to Codman & Shurtleff, Inc. in fiscal 2001 and 2000,
respectively. Codman & Shurtleff, Inc. also sells its own passive hand-held
instruments under the MALIS(R) tradename which are used in conjunction with our
neurosurgery bipolar system.
[10]
Bident International, L.L.C. In 1999, we entered into a supply and
distribution agreement with Bident International, L.L.C., an affiliate of
Garfield Refining Company, covering the sale of our Bident(R) bipolar dental
system in the field of dentistry. We have recently decided to change the
marketing plan for our dental products and are in the process of terminating our
distribution agreement with Bident International, LLC.
Boston Scientific Corporation. In 1993, we entered into a supply and
distribution agreement with Boston Scientific Corporation covering the exclusive
worldwide marketing rights of our bipolar coagulators for use in the fields of
gastroenterology and endoscopy, through March 2002. In Feburary 2002, we
terminated this agreement by mutual consent and entered into a new agreement
with Boston Scientific Corporation to provide primarily product support for the
installed base of Boston Scientific's "Symmetry Endo-Bipolar Generator" and the
Mini- Symmetry(TM) generators.
Our neurosurgery bipolar systems are sold in certain foreign markets by
Codman & Shurtleff, Inc. Prior to sales in certain foreign markets, we will need
to comply with applicable foreign government regulations.
Our business is not affected to any material extent by seasonal factors.
Competition
We believe that principal competitive factors with our bipolar products
are product features and quality, safety, ease of use, cost, acceptance by
leading physicians, and improved patient outcomes. We believe that our
DualWave(TM) technology, which delivers both bipolar cutting and bipolar
coagulation with two separate waveforms, distinguishes our bipolar
electrosurgical systems from electrosurgical systems sold by other entities,
which do not offer both bipolar cutting and bipolar coagulation. We believe that
our unique bipolar electrosurgical products offer enhanced capabilities and
safety advantages as compared to other electrosurgical systems.
The medical device industry is intensely competitive in almost all segments
and tends to be dominated in large more mature markets by a relatively small
group of large and well financed companies. We also compete with smaller,
entrepreneurial companies. There can be no assurance that these or other
companies will not succeed in developing, or have not already developed,
technologies or products that are more effective than ours or that would render
our technology or products obsolete or uncompetitive.
Neurosurgery
- ------------
In neurosurgery, we believe that we are the principal manufacturer of
bipolar electrosurgical systems. Our neurosurgery bipolar system competes
against manufacturers of electrosurgical systems, including ValleyLab and Erbe.
In addition, we compete with other technologies and a variety of tissue removal
systems designed for removing brain and cranial-based tumors, such as an
ultrasonic tissue aspiration system also manufactured by ValleyLab.
[11]
Dental Market
- -------------
In the dental market, we believe that we are the only manufacturer of
bipolar electrosurgical systems. Our Bident(R) bipolar dental system competes
with monopolar electrosurgical systems manufactured by Ellman, and laser and
other monopolar electrosurgical systems manufactured by other companies.
Other Surgical Markets
- ----------------------
In other surgical markets, our bipolar generator and disposable
instruments will compete with large companies, such as ValleyLab, Ellman and
Conmed, which manufacture and sell electrosurgical medical devices. Our systems
will also compete with laser systems and other technologies manufactured or
utilized by other companies.
Research and Development
We are continually working on enhancements to our generator products and
on new disposable instrumentation along with other products to meet the needs of
surgeons in various surgical disciplines. We also are exploring new applications
for our DualWave(TM) technology in other clinical and surgical markets. In
September 2002, we entered into a development agreement with Stryker Corporation
for a new product for use in a field outside of the neurosurgery and dental
fields.
For the 2002, 2001 and 2000 fiscal years, we expended $360,111, $352,773
and $338,318, respectively, for research and development. We anticipate that we
will continue to incur research and development costs in connection with
development of products.
Substantially all of our research and development is conducted internally.
In the 2003 fiscal year, we anticipate that we will fund all our research and
development with current assets and cash flows from operations.
Government Regulation
The marketing and sale of our products in the United States is governed by
the Federal Food, Drug and Cosmetic Act (the "Act") administered by the FDA, as
well as varying degrees of regulation by a number of state and foreign
governmental agencies. The Act requires certain clearances from the FDA before
medical devices can be marketed.
FDA regulations are wide ranging and govern, among other things:
* product design and development;
* product testing;
* product labeling;
* product storage;
* premarket clearance or approval;
* advertising and promotion; and
* product sales and distribution.
Noncompliance with applicable regulatory requirements can result in
enforcement action, which may include:
[12]
* warning letters;
* fines, injunctions and civil penalties against us;
* recall or seizure of our products;
* operating restrictions, partial suspension or total shutdown
of our production;
* refusing our requests for premarket clearance or approval of
new products;
* withdrawing product approvals already granted; and
* criminal prosecution.
All medical devices introduced into the market since 1976, which include
substantially all of our products, are required by the FDA as a condition of
sale and marketing to secure either a 510(k) premarket notification clearance or
an approved premarket approval application ("PMA"). A 510(k) premarket
notification clearance indicates FDA agreement with an applicant's determination
that the product for which clearance has been sought is substantially equivalent
to another medical device that was on the market prior to 1976 or that has
received 510(k) premarketing notification clearance. The process of obtaining a
510(k) premarket notification clearance can typically take several months and
commonly involves the submission of limited clinical data and supporting
information while the PMA process typically will last more than a year and
requires the submission of significant quantities of clinical data and
manufacturing information.
To comply with the FDA regulations, we may incur substantial costs relating
to laboratory and clinical testing of new and existing products and the
preparation and filing of documents in formats required by the FDA. In addition,
we may also encounter delays in bringing new or existing devices to market as a
result of being required by the FDA and foreign governmental authorities to
conduct and document additional investigations of product safety and
effectiveness.
For European distribution, we have received ISO 9001 certification for
our neurosurgery bipolar system and are allowed to use the CE mark on our
neurosurgery bipolar system after assembling appropriate documentation. Failure
to maintain the CE Mark will preclude our distributor from selling our products
in Europe. We cannot assure you that we will be successful in maintaining
certification requirements.
We have received 510(k) clearance to market our bipolar electrosurgical
generator and disposable instrumentation. We have also received clearance to
market our Bident(R) bipolar dental system for dental procedures. We cannot
assure you that we will be able to obtain necessary clearances or approvals to
market any other products, or existing products for new intended uses, on a
timely basis, if at all. Delays in receipt or failure to receive clearances or
approvals, the loss of previously received clearances or approvals, or failure
to comply with existing or future regulatory requirements could have a material
adverse effect on business, financial condition, results of operations and
future growth prospects.
Under FDA regulations, after a device receives 510(k) clearance, any
modification that could significantly affect its safety or effectiveness, or
that would constitute a major change in the intended use of the device,
technology, materials, packaging, and certain manufacturing process may require
a new 510(k) clearance. The FDA requires a manufacturer to make this
determination in the first instance, but the FDA can review any such decision,
and if it disagrees it can require a manufacturer to obtain a new 510(k)
clearance or it can seek enforcement action against the manufacturer.
[13]
We are also required to maintain compliance with the Quality System
Regulation, or QSR. The QSR incorporates the requirements of Good Manufacturing
Practice and relates to product design, testing, and manufacturing quality
assurance, as well as the maintenance of records and documentation. The FDA
enforces the QSR through inspections. We cannot assure you that we or our key
components suppliers are or will continue to be in compliance, will not
encounter any manufacturing difficulties, or that we or any of our
subcontractors or key component suppliers will be able to maintain compliance
with regulatory requirements. Failure to do so will have a material adverse
effect on our business, financial condition, results of operations and future
growth prospects.
We may not promote or advertise our products for uses not within the scope
of our clearances or approvals or make unsupported safety and effectiveness
claims. We believe that we are in material compliance with regulations
promulgated by the FDA, and that such compliance has been and is anticipated to
be without adverse effect on our business.
Patents and Trademarks
Our ability to compete in an effective manner depends in part on
developing and maintaining proprietary aspects of our bipolar technology. We own
two principal United States patents that are directed towards our DualWave(TM)
bipolar technology used in our bipolar electrosurgical systems. Our first
patent, which was issued on May 27, 1986, is set to expire on May 27, 2003. Our
second patent was issued on June 17, 1994. Since our current bipolar
electrosurgical generators are based on the combination of both of these patents
and other know-how and trade secrets, we do not believe that the expiration of
our first patent will adversely affect our business.
We also own two United States patents, which are used in our disposable
hand-held bipolar instruments, and we have applied for United States patents on
additional disposable instrumentation and electronic circuitry. Our practice and
experience is to apply for patents that are important to the development or sale
of a product.
Dr. Leonard I. Malis, one our principal shareholders and directors, has
also entered into an agreement with us to license the MALIS(R) trademark to us,
at no cost, to the extent the name has not been licensed to Codman & Shurtleff,
Inc.
We cannot assure you that the patents we have obtained, or any patents
that we may obtain as a result of our patent applications, will provide any
competitive advantages for our products or that they will not be successfully
challenged, invalidated or circumvented in the future. In addition, we cannot
assure you that competitors, many of whom have substantial resources and have
made substantial investments in competing technologies, will not seek to apply
for and obtain patents that will prevent, limit or interfere with our ability to
make, use and sell our products either in the United States or in international
markets.
Other companies and entities have filed patent applications or have been
issued patents relating to monopolar and/or bipolar electrosurgical methods and
devices. We do not believe that our products currently infringe any valid and
enforceable claims of the issued patents that we have reviewed. We cannot assure
you that we will not have to defend ourselves in court against allegations of
infringement of third-party patents.
[14]
In addition to patents, we rely on trade secrets and proprietary know-how,
which we seek to protect, in part, through confidentiality and proprietary
information agreements. We require our key employees and consultants to execute
confidentiality agreements upon the commencement of an employment or consulting
relationship with us. These agreements generally provide that all confidential
information developed or made known to the individual by us during the course of
the individual's relationship with us, is to be kept confidential and not
disclosed to third parties. These agreements also generally provide that
inventions conceived by the individual in the course of rendering services to us
shall be our exclusive property. We cannot assure you that employees will not
breach the agreements, that we would have adequate remedies for any breach or
that our trade secrets will not otherwise become known to or be independently
developed by competitors.
Employees
At September 30, 2002, we and our subsidiaries had 22 full-time employees,
including executive officers. From time to time we retain part-time employees,
engineering consultants, scientists and other consultants. All full-time
employees participate in our health benefit plan. None of our employees are
represented by a union or covered by a collective bargaining agreement. We
consider our relationship with our employees to be satisfactory.
Forward Looking Statements
The information provided in this report may contain forward looking
statements or statements which arguably imply or suggest certain things about
our future. These include, but are not limited to statements about: (1) any
competitive advantage we may have as a result of our installed base of
electrosurgical generators in the field of neurosurgery; (2) our belief that our
products exceed industry standards or favorably compete with other companies'
new technological advancements; (3) the future success of products and
disposable instrumentation in the field of neurosurgery and the dental market;
and (4) our ability to attract distributors for our products outside of
neurosurgery, and the acceptance and continued acceptance of our products in
those markets. These statements are based on assumptions that we believe are
reasonable, but a number of factors could cause our actual results to differ
materially from those expressed or implied by these statements. We do not intend
to update these forward looking statements. Investors are advised to review the
Additional Cautionary Statements section, which follows the Management's
Discussion and Analysis of Financial Condition and Results of Operations section
(Item 7) of this Report, for more information about risks that could affect our
financial results.
[15]
Item 2. PROPERTIES.
----------
We currently lease approximately 4,200 square feet of office and warehouse
space at a base monthly rent of $4,716 (with increases based on increases in the
producer price index) in an office building in Oaks, Pennsylvania, approximately
12 miles northwest of Philadelphia, Pennsylvania. The current lease is for a
term of five years ending June 30, 2005. Our manufacturing operations are
conducted in a building owned by our wholly owned subsidiary, Diversified
Electronics Company, Inc., with approximately 15,000 square feet in
Philadelphia, Pennsylvania.
Item 3. LEGAL PROCEEDINGS.
-----------------
From time to time we are subject to litigation claims. As of September 30,
2002, there are no material pending legal proceedings to which we are a party or
to which any of our property is the subject.
On September 19, 2002, we were served with a Complaint that was filed in
the Superior Court of the State of Arizona, County of Maricopa entitled
Jeffrey Turner and Cathryn Turner, husband and wife, individually, and on
- -------------------------------------------------------------------------
behalf of Morgan Rose Turner, a Minor v. Phoenix Children's Hospital, Inc.,
- ---------------------------------------------------------------------------
Valley Forge Scientific Corp., et al (CV 2002-010791)
- ------------------------------------
in which we are named as one of the defendants. The plaintiff seeks an
unspecified amount of damages for alleged injuries sustained in a surgery that
took place in June 2000. Our products liability insurance carrier is providing
our defense in this matter. In an answer that was filed on November 26, 2002, we
deny any liability. We will vigorously defend ourselves in this matter.
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
---------------------------------------------------
No matters were submitted to a vote of the securityholders during the
fourth quarter of fiscal year 2002.
PART II
-------
Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY
-------------------------------------
AND RELATED STOCKHOLDER MATTERS.
-------------------------------
Our Common Stock, no par value, is quoted on the Boston Stock Exchange
under the symbol VLF, and traded in the over-the- counter market, and is
included in the Nasdaq - Small Cap Issues under the symbol "VLFG." The table
below sets forth the range of high and low closing bid quotations per share of
Common Stock as reported on Nasdaq. Quotations represent prices between
dealers and do not necessarily represent actual transactions. None of the prices
shown reflect retail mark-ups, mark-downs, or commissions.
COMMON STOCK High-Bid Low-Bid
Fiscal 2002:
First Quarter .......... $2.95 $2.20
Second Quarter.......... 3.15 2.20
Third Quarter........... 3.05 2.38
Fourth Quarter.......... 2.60 1.26
Fiscal 2001:
First Quarter........... $1.63 $0.87
Second Quarter.......... 3.25 1.34
Third Quarter........... 3.25 1.06
Fourth Quarter.......... 3.20 2.75
At December 13, 2002, we had 107 shareholders of record.
We have not paid any dividends to date, nor do we expect to do so in the
foreseeable future.
[16]
Item 6. SELECTED FINANCIAL DATA
The selected financial data set forth below should be read in conjunction
with the "Management's Discussion and Analysis of Financial Condition and
Results of Operations" and our financial statements and notes thereto appearing
elsewhere in this Form 10-K.
Statement of Operations Data:
For Fiscal Year Ended:
---------------------
2002 2001 2000 1999 1998
---- ---- ---- ---- ----
Net Sales $5,021,931 $5,263,938 $4,397,939 $3,721,528 $3,879,977
Income (loss) from
Operations 632,000 485,746 (110,817) (197,810) (63,521)
Net Income (loss) $ 380,527 $ 330,221 $ (54,312) $ (124,973) $ (34,374)
========== ========== ========= ========== ==========
Basic Earnings (loss)
per share $0.05 $0.04 $(0.01) $(0.02) $(0.00)
===== ===== ====== ====== ======
Diluted Earnings
(loss) per share $0.05 $0.04 $(0.01) $(0.02) $(0.00)
===== ===== ====== ====== ======
Balance Sheet Data:
At September 30, 2002 2001 2000 1999 1998
--------------- ---- ---- ---- ---- ----
Current Assets $3,981,746 $3,516,992 $3,093,698 $3,161,394 $3,216,510
Total Assets 4,570,035 4,171,214 3,852,079 4,034,443 4,204,211
Current Liabilities 353,281 283,186 182,185 166,618 161,120
Long Term Liabilities 14,357 19,280 20,661 16,885 18,445
Retained Earnings
(deficit) 500,551 120,024 (210,197) (155,885) (30,912)
Stockholders' Equity 4,202,397 3,868,746 3,649,233 3,850,940 4,024,646
Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
-------------------------------------------------
CONDITION AND RESULTS OF OPERATIONS
----------------------------------
The following discussion should be read in conjunction with the
consolidated financial statements and notes thereto appearing elsewhere in this
Form 10-K. Statements in this Management's Discussion and Analysis of Financial
Condition and Results of Operations which express that we "believe,"
"anticipate," "expect" or "plan to" as well as other statements which are not
historical fact, are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Actual events or results may
differ materially as a result of the risks and uncertainties described herein
and elsewhere including, but not limited to, those factors discussed in
"ADDITIONAL CAUTIONARY STATEMENTS section in this Item 7. We do not intend to
update these forward looking statements.
[17]
Overview
We design, develop, manufacture and sell medical devices. Our core business
is in our bipolar electrosurgical generators and related instrumentation, based
on our DualWave(TM) technology. Our bipolar systems allow a surgeon or dentist
to cut tissue in a manner that minimizes collateral damage to surrounding
healthy tissue and to coagulate blood vessels quickly, safely and efficiently.
By essentially eliminating damage to surrounding healthy tissue, the surgeon can
work safely in direct contact with nerves, blood vessels, bone and metal
implants. Our bipolar systems are designed to replace other surgical tools, such
as monopolar systems, lasers and conventional instruments, used in soft tissue
surgery.
Our DualWave(TM) technology is applicable to many surgical markets. Our
bipolar systems are currently used to perform many types of neurosurgery, spine
surgery and dental surgery. We have entered into a worldwide exclusive
distribution agreement with Codman & Shurtleff, Inc., a subsidiary of Johnson &
Johnson, Inc., to market our neurosurgery bipolar systems.
Historically, we have derived a significant portion of our sales from our
neurosurgery bipolar system. Sales revenue from our Bident(R) bipolar dental
system commenced in the 2000 fiscal year. Our strategy is to increase sales of
our Bident(R) bipolar dental system by directly selling our products to an
expanded base of national dental product dealers, expand the offerings of
products in the field of neurosurgery and broaden the market for our products in
other clinical and surgical markets that have a need for bipolar electrosurgery.
Our strategy also includes using our DualWave(TM) technology and sales of our
bipolar generators to drive sales of complementary disposable hand-held
instruments and products.
Critical Accounting Policies and Estimates
The following "Management's Discussion and Analysis of Financial Condition
and Results of Operations", as well as disclosures included elsewhere in this
Form 10-K, are based upon our audited consolidated financial statements, which
have been prepared in accordance with accounting principles generally accepted
in the United States. The preparation of these financial statements requires us
to make estimates and judgments that affect the reported amounts of assets,
liabilities, revenues and expenses, and related disclosure of contingencies. On
an ongoing basis, we evaluate the estimates used, including those related to
product returns, bad debts, inventory valuation, impairments of tangible and
intangible assets, income taxes, warranty obligations, other accruals,
contingencies and litigation. We base our estimates on historical experience,
current conditions and on various other assumptions that are believed to be
reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources as well as identifying and assessing our
accounting treatment with respect to commitments and contingencies. Actual
results may differ from these estimates under different assumptions or
conditions. We believe the following critical accounting policies involve more
significant judgments and estimates used in the preparation of the consolidated
financial statements.
[18]
We maintain an allowance for doubtful accounts for estimated losses
resulting from the potential inability of our customers to make required
payments. If the financial condition of our customers were to deteriorate,
resulting in an impairment of their ability to make payments, additional
allowances may be required.
We provide for the estimated cost of product returns based upon historical
experience and any known conditions or circumstances. Our warranty obligation is
affected primarily by product that does not meet specifications and performance
requirements within the applicable warranty period and any related costs of
addressing such matters. Should actual incidences of product not meeting
specifications and performance requirements differ from our estimates, revisions
to the estimated warranty liability may be required.
We value inventory at the lower of cost or market and write down the value
of inventory for estimated obsolescence or unmarketable inventory. An inventory
reserve is maintained based upon historical data of actual inventory written off
and for known conditions and circumstances. Should actual product marketability
be affected by conditions that are different from those projected by management,
revisions to the estimated inventory reserve may be required.
In accordance with the provisions of Statement of Financial Accounting
Standards ("SFAS") No. 123, "Accounting for Stock-Based Compensation" ("SFAS
123"), we have elected to account for stock-based compensation plans in
accordance with Accounting Principles Board Opinion No. 25, "Accounting for
Stock Issued to Employees" ("APB 25"), and related interpretations. We disclose
the summary of pro forma effects to reported net income as if we had elected to
recognize compensation cost based on the fair value of stock based awards to
employees of Valley Forge Scientific Corp. as prescribed by SFAS 123.
Results of Operations
Summary
Sales of $5,021,931, for fiscal 2002 were 5% less than sales of $5,263,485
for fiscal 2001 and 14% greater than sales of $4,397,939 for fiscal 2000.
Operating income increased by 30% to $632,000 in fiscal 2002 from $485,746 in
fiscal 2001. In fiscal 2000, we had a loss from operations of $110,817. Net
income for fiscal 2002 increased by 15% to $380,527 from net income of $330,221
for fiscal 2001. In fiscal 2000, we had a net loss of $54,312.
Revenues
Sales of $5,021,931 in fiscal 2002 reflect an increase in sales volume to
Codman & Shurtleff, Inc., the distributor of our products in the neurosurgery
market, and a decrease in sales volume to Bident International, LLC, which
distributed our products in the dental market in fiscal 2002. In fiscal 2002,
Codman & Shurtleff, Inc. accounted for 90% of our sales, as compared to 79% of
sales for fiscal 2001 and 84% of our sales for fiscal 2000. Sales of the
Bident(R) bipolar dental system were 7% of total sales for fiscal 2002 as
compared to 19% of sales for fiscal 2001 and 7% of our sales for fiscal 2000.
[19]
Sales to Codman & Shurtleff, Inc. in fiscal 2002 reflected growth in sales
volume of our bipolar generators, irrigators and accessories. Sales volume of
our disposable cord/tubing sets in fiscal 2002 were essentially constant with
sales volume in fiscal 2001. Codman & Shurtleff, Inc.'s marketing plan for our
disposable hand-held instruments did not materialize as we expected and we only
achieved minimal market penetration and nominal sales of disposable hand-held
instruments in fiscal 2002. We are in discussions with Codman & Shurtleff, Inc.
regarding the refinement and expansion our disposable hand-held instrument
product offering for re-introduction in fiscal 2003. At this time, we cannot
forecast the contribution sales of these instruments will have in fiscal 2003.
Our distribution agreement with Codman & Shurtleff, Inc. for the exclusive
worldwide right to sell our neurosurgery bipolar systems and certain other
products in the field of neurocranial and neurospinal surgery continues through
December 31, 2003.
In January 2002, Bident International, LLC, the distributor of our dental
products, began using a dealer sales representative as the primary means of
selling our dental products to dental product dealers. During fiscal 2002,
Bident International, LLC, was not successful in establishing relationships with
major dental product dealers and we have recently decided to change the
marketing plan for our dental products. Our new marketing plan does not involve
Bident International, LLC and focuses on direct marketing and sales of our
Bident(R) bipolar dental system to national dental product dealers. We are in
the process of terminating our distribution agreement with Bident International,
LLC. We feel that the new marketing plan will achieve greater market penetration
of our dental products in the dental market. We are in the early stages of
establishing the infrastructure to support our dental dealer marketing effort
and we have planned a marketing campaign for the first half of calendar 2003
targeting dentists, periodontists and oral surgeons, with a direct consumer
approach.
In fiscal 2002, 59% of our sales related to sales of bipolar
electrosurgical generators, irrigators and accessories as compared to
approximately 57% and 59% of our sales in fiscal 2001 and 2000, respectively.
Sales of disposable products accounted for approximately $1,669,000, or 33% of
our sales, in fiscal 2002 as compared to approximately $1,999,000, or 38% of our
sales, in fiscal 2001 and approximately $1,763,000, or 40% of our sales, in
fiscal 2000. The reduced sales in disposable products reflect reduced sales of
neurosurgery hand-held instruments and reduced sales of dental products.
Cost of Product Sales
Cost of sales for fiscal 2002 was $2,463,209, or 49% of sales, compared
with $2,692,036, or 51% of sales, for fiscal 2001. During fiscal 2000, cost of
sales was $2,443,406, or 56% of sales. Gross margin was 51% for fiscal 2002 as
compared to 49% for fiscal 2001 and 44% for fiscal 2000.
The increase in gross margin as a percentage of sales is attributable to
changes in product mix and increased manufacturing efficiencies. We cannot be
sure that gross margins will remain at current levels or show improvement in the
future due to the distribution channels used, product mix, and fluctuation in
manufacturing production levels and overhead costs as new products are
introduced. In addition, inefficiencies in manufacturing new products and the
distribution channels utilized to sell those products may adversely impact gross
margin.
[20]
Operating Expenses
Selling, general and administrative expenses decreased to $1,503,001, or
30% of sales, in fiscal 2002, from $1,652,289, or 31% of sales, in fiscal 2001,
and from $1,646,438, or 37% of sales, in fiscal 2000. Overall, the decrease in
selling, general and administrative expenses in absolute dollars was primarily
attributable to increased cost cutting efforts and elimination of administrative
positions.
Research and development expenses were $360,111, or 7% of sales, in fiscal
2002, $352,773, or 7% of sales, in fiscal 2001, and $338,318, or 8% of sales, in
fiscal 2000. We will continue to invest in research and development to expand
our technological base for use in both existing and additional clinical areas.
In September 2002, we entered into a development agreement with Stryker
Corporation to expand the use of our DualWave(TM) technology for use in a field
outside of the neurosurgery and dental fields.
As a result of our cost cutting efforts in both cost of sales and selling
general and administrative expenses and changes in product mix, our operating
income in fiscal 2002 increased by 30% to $632,000 from $485,746 in fiscal 2001,
and compared to a loss from operations of $110,817 in fiscal 2000.
Other Income and Expense, net
Other income and expense, net, decreased for fiscal 2002 to $23,111 from
$39,428 for fiscal 2001 and from $38,243 for fiscal 2000 due primarily to lower
interest rates on the short-term investments for our cash balances. At the end
of fiscal 2002, we had $2,543,898 in cash and cash equivalents as compared to
$1,500,622 at the end of fiscal 2001 and $965,240 at the end of fiscal 2000.
Income Tax Benefit/(Provision)
The provision for income taxes was $274,584 for fiscal 2002 as compared to
$194,953 for fiscal 2001 and an income tax benefit of $18,262 for fiscal 2000.
Our effective tax rate in fiscal 2002 was approximately 42% as compared to
approximately 37% in fiscal 2001 and approximately (25%) in fiscal 2000.
Net Income (Loss)
Net income increased by 15% to $380,527 for fiscal 2002, as compared to
net income of $330,221 for fiscal 2001, and a net loss of $54,312 for fiscal
2000. Basic and diluted income per share was $.05 for fiscal 2002 as compared to
basic and diluted income per share of $.04 for fiscal 2001 and a loss per basic
and diluted share of $.01 for fiscal 2000. Net income for the current fiscal
year reflects an increase in gross margin and reduced selling and general
administrative expenses. Although we have been profitable on a quarterly basis
since the third quarter of fiscal 2000, we cannot be sure that we can sustain
revenue growth or profitability.
Liquidity and Capital Resources
At the end of fiscal 2002, we had $3,628,465 in working capital compared
to $3,233,806 at the end of fiscal 2001 and $2,911,513 at the end of fiscal
2000. The primary measures of our liquidity are cash, cash equivalents, accounts
receivable and inventory balances, as well as our borrowing ability. The cash
equivalents are highly liquid with original maturities of ninety days or less.
[21]
Cash generated by operating activities was $1,059,755 for fiscal 2002 as
compared to $678,990 generated in fiscal 2001. The cash generated by operating
activities was mainly attributable to increased operating profits, a decrease in
accounts receivable, inventory and deferred tax assets and an increase in
accounts payable, accrued expenses and income taxes payable. This was partially
offset by an increase in prepaid items.
In fiscal 2002, accounts receivable net of allowances decreased by
$267,211 to a total of $337,939 at the end of fiscal 2002. The decrease in
accounts receivable was principally due to an improved collection process,
timing of shipments and reduced sales levels for fiscal 2002.
In fiscal 2002, inventories decreased by $316,704 to a total of $882,832 at
the end of fiscal 2002 compared to $1,199,536 at the end of fiscal 2001. The
decrease was primarily due to improved inventory management and reduced sales
levels for fiscal 2002. Inventories were kept at these levels primarily to
support anticipated future sales activity.
In fiscal 2002, we received net proceeds of $55,825 from the repayment of
employee loans. We also used approximately $25,000 for the purchase of property
and intangible assets. Net property and equipment decreased to $136,131 at the
end of fiscal 2002 as compared to $145,800 for fiscal 2001.
In August 2002, our Board of Directors terminated our then existing stock
repurchase program and authorized a new repurchase program to purchase up to
200,000 shares of our common stock. Cash used for financing activities was
$46,878 in fiscal 2002 as a result of the repurchase of 26,500 shares of our
common stock in fiscal 2002 pursuant to the stock repurchase program. All 26,500
shares of common stock repurchased were retired or were in the process of being
retired as of September 30, 2002. From October 1, 2002 to November 30, 2002, we
purchased an additional 36,600 shares of our common stock pursuant to the stock
repurchase program at a cost of $57,882.
At September 30, 2002, we had cash and cash equivalents of $2,543,898. We
plan to finance our operating and capital needs principally with cash flows from
operations and existing balances of cash and cash equivalents, which we believe
will be sufficient to fund our operations in the near future. However, should it
be necessary, we believe we could borrow adequate funds at competitive rates and
terms. Our future liquidity and capital requirements will depend on numerous
factors, including the success in commercializing our existing products,
development and commercialization of products in other clinical markets, the
ability of our suppliers to continue to meet our demand at current prices, the
status of regulatory approvals and competition.
We have a line of credit of $1,000,000 with First Union National Bank,
which calls for interest to be charged at the bank's national commercial rate.
The credit accommodation is unsecured and requires us to have a tangible net
worth of no less than $3,000,000. Our current tangible net worth exceeds
$3,000,000 at September 30, 2002. There was no outstanding balance on this line.
[22]
Non-Audit Services Performed by External Auditors
Pursuant to Section 10A(i)(2) of the Securities Exchange Act of 1934, as
added by Section 202 of the Sarbanes-Oxley Act of 2002, we are responsible for
disclosing to investors the non- audit services approved by our Audit Committee
to be performed by Samuel Klein and Company, our external auditor. Non-audit
services are defined in the law as services other than those provided in
connection with an audit or a review of the financial statements of the company.
During the period covered by this filing, our Audit Committee approved non-audit
tax compliance services in connection with the preparation of our tax returns,
which subsequently were or are being performed by Samuel Klein and Company.
Forward Looking Statements
The information provided in this report may contain "forward looking"
statements or statements which arguably imply or suggest certain things about
our future. Statements which express that we "believe", "anticipate", "expect",
or "plan to" as well as other statements which are not historical fact, are
forward looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward looking statements include, but are
not limited to statements about: (1) any competitive advantage we may have as a
result of our installed base of electrosurgical generators in the field of
neurosurgery; (2) our belief that our products exceed industry standards or
favorably compete with other companies' new technological advancements; (3) the
future success of products and disposable instrumentation in the field of
neurosurgery and the dental market; and (4) our ability to attract distributors
for our products outside of neurosurgery, and the acceptance and continue
acceptance of our products in those markets. These statements are based on
assumptions that we believe are reasonable, but a number of factors could cause
our actual results to differ materially from those expressed or implied by these
statements We do not intend to update these forward looking statements. You are
advised to review the "Additional Cautionary Statements" section below for more
information about risks that could affect the financial results of Valley Forge
Scientific.
Additional Cautionary Statements
We Face Intense Competition
- ---------------------------
The markets for our current and future products are intensely competitive.
Some surgical procedures which utilize or could utilize our products could
potentially be replaced or reduced in importance by alternative medical
procedures or new drugs which could render our products obsolete or
uncompetitive in these markets.
Our Growth Depends on Introducing New Products and the Market
- -------------------------------------------------------------
Penetration by Third Party Distributors
- ---------------------------------------
Our growth depends on the acceptance of our products in the marketplace,
the market penetration achieved by the companies that we utilize, sell to, and
rely on, to distribute our products, and our ability to introduce new and
innovative products that meet the needs of medical professionals. There can be
no assurance that we will be able to continue to introduce new and innovative
products or that the products we introduce, or have introduced, will be widely
accepted by the marketplace, or that companies which we contract with to
distribute our products will continue to achieve market penetration in the field
of neurosurgery and achieve market penetration in the dental market and
surgical disciplines and markets outside of neurosurgery. Our failure to
continue to introduce new products or gain wide spread acceptance of our
products would adversely affect our operations.
[23]
We Depend on Attracting New Distributors for Our Products
- ---------------------------------------------------------
In order to successfully commercialize our products in new markets, we will
need to enter into distribution arrangements with companies who can distribute
our products in those markets successfully.
Our Products are Extensively Regulated Which Could Delay Product
- ----------------------------------------------------------------
Introduction or Halt Sales
- --------------------------
The process of obtaining and maintaining required regulatory approvals is
lengthy, expensive and uncertain. Although we have not experienced any
substantial regulatory delays to date, there is no assurance that delays will
not occur in the future, which could have a significant adverse effect on our
ability to introduce new products on a timely basis. Regulatory agencies
periodically inspect our manufacturing facilities to ascertain compliance with
"good manufacturing practices" and can subject approved products to additional
testing and surveillance programs. Failure to comply with applicable regulatory
requirements can, among other things, result in fines, suspensions of regulatory
approvals, product recalls, operating restrictions and criminal penalties. While
we believe that we are currently in compliance, if we fail to comply with
regulatory requirements, it could have an adverse effect on our results of
operations and financial condition.
A Significant Amount of Our Business Comes From One Customer.
- ------------------------------------------------------------
Codman & Shurtleff, Inc. accounted for 90% of our sales in fiscal 2002, and
79% and 84% of our sales in fiscal 2001 and 2000, respectively. Any
cancellation, deferral or significant reduction in sales to Codman & Shurtleff,
Inc. could seriously harm our business, financial condition and results of
operations.
We Face Uncertainty Over Reimbursement
- --------------------------------------
Failure by physicians, hospitals and other users of our products to obtain
sufficient reimbursement from health care payors for procedures in which our
products are used or adverse changes in governmental and private third-party
payors' policies toward reimbursement for such procedures would have a material
adverse effect on our business, financial condition, results of operations and
future growth prospects.
We May Be Unable to Effectively Protect Our Intellectual Property
- ----------------------------------------------------------------
Our ability to compete effectively depends in part on developing and
maintaining the proprietary aspects of our bipolar technology. We cannot assure
you that the patents we have obtained, or any patents we may obtain, will
provide any competitive advantages for our products, or that we will be able to
maintain a competitive advantage after our patents expire. We also cannot assure
you that those patents will not be successfully challenged, invalidated or
circumvented in the future. In addition, we cannot assure you that competitors,
many of which have substantial resources and have made substantial investments
in competing technologies, have not already applied for or obtained, or will not
seek to apply for and obtain, patents that will prevent, limit or interfere with
our ability to make, use and sell our products either in the United States or in
international markets. Patent applications are maintained in secrecy for a
period after filing. We may not be aware of all of the patents and patent
applications potentially adverse to our interests.
[24]
We May Become Subject to a Patent Litigation
- --------------------------------------------
The medical device industry has been characterized by extensive litigation
regarding patents and other intellectual property rights, and companies in the
medical device industry have employed intellectual property litigation to gain a
competitive advantage. We cannot assure you that we will not become subject to
patent infringement claims or litigation or interference proceedings declared by
the United States Patent and Trademark Office to determine the priority of
invention.
We May have Product Liability Claims
- ------------------------------------
Our products involve a risk of product liability claims. Although we
maintain product liability insurance at coverage levels, which we believe are
adequate, there is no assurance that, if we were to incur substantial liability
for product liability claims, insurance would provide adequate coverage against
such liability.
Our Operating Results May Fluctuate
- -----------------------------------
We have experienced operating losses at various times since our inception.
Our results of operations may fluctuate significantly from quarter to quarter
based on numerous factors including the following:
* the introduction of new product lines;
* the level of market acceptance of our products;
* achievement of research and development milestones;
* timing of the receipt of orders from, and product shipments
to, our distributors;
* timing of expenditures;
* manufacturing or supply delays;
* the time needed to educate and train a distributor's sales
force;
* product returns; and
* receipt of necessary regulation approvals.
Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
----------------------------------------------------------
Not Applicable.
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
-------------------------------------------
See Index to Financial Statements and Financial
Statement Schedules on page F-1 herein. Selected quarterly
financial data is set forth in Note 15 to the Financial Statements.
[25]
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
------------------------------------------------
ACCOUNTING AND FINANCIAL DISCLOSURE.
- -----------------------------------
Not applicable.
PART III
--------
Item 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.
--------------------------------------------------
The information concerning directors and officers called for by Item 10 of
Form 10-K will be set forth either: (i) in our Definitive Proxy Statement for
our Annual Meeting of Stockholders, or (ii) in an amendment to this Annual
Report on Form 10-K, which in either case will be filed within 120 days after
the end of the fiscal year covered by this Annual Report on Form 10-K, and is
incorporated herein by reference.
Item 11. EXECUTIVE COMPENSATION.
----------------------
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
-----------------------------------------------
AND MANAGEMENTAND RELATED STOCKHOLDER MATTERS.
---------------------------------------------
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
----------------------------------------------
The information called for by Items 11, 12 and 13 of Form 10-K will be set
forth either: (i) in our Definitive Proxy Statement for our Annual Meeting of
Stockholders, or (ii) in an amendment to this Annual Report on Form 10-K, which
in either case will be filed within 120 days after the end of the fiscal year
covered by this Annual Report on Form 10-K, and is incorporated herein by
reference.
PART IV
-------
Item 14. CONTROLS AND PROCEDURES
-----------------------
Within 90 days of the filing of this report, the Company's Chief Executive
Officer/ Principal Financial Officer has conducted an evaluation of the
effectiveness of the design and operation of our disclosure controls and
procedures pursuant to Exchange Act Rule 13a-14 and 15d-14. Based on that
evaluation, our Chief Executive Officer/Principal Financial Officer concluded
that our disclosure controls and procedures are effective to make known to him
in a timely fashion material information related to the Company required to be
filed in this report. There have been no significant changes in the Company's
internal controls or in other factors that could significantly affect internal
controls subsequent to the date of his evaluation.
While we believe the present design of our disclosure controls and
procedures is effective to make known to our senior management in a timely
fashion all material information concerning our business, we will continue to
improve the design and effectiveness of our disclosure controls and procedures
to the extent necessary in the future to provide our senior management with
timely access to such material information, and to correct any deficiencies that
we may discover in the future.
[26]
Item 15 EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K.
---------------------------------------------------------------
a. and d. Financial Statements and Financial Statement Schedules.
See Index to Financial Statements and Financial Statement
Schedules on Page F-1, herein.
b. Reports on Form 8-K.
None.
c. Exhibits
The following is a list of exhibits filed as part of this annual report
on Form 10-K. Where so indicated by footnote, exhibits which were
previously filed are incorporated by reference. For exhibits
incorporated by reference, the location of the exhibit in the previous
filing is indicated in parentheses.
(2) Agreement and Plan of Merger.
(a) Agreement and Plan of Merger between Valley Forge Scientific
Corp. and Diversified Electronic Corporation dated August 31,
1994. (3)
(3) Articles of Incorporation and By-Laws.
(a) Articles of Incorporation, restated to include amendment to
Articles of Incorporation dated August 26, 1999. (8) (Exhibit
3(a))
(b) Second Amended and Restated By-Laws of the Company. (12)
(4) Instruments defining the Rights of Security Holders, including
Indentures.
(a) Form of Common Stock Certificate - (1) (Exhibit 4(a)).
(10) Material Contracts.
(a) 2001 Stock Plan (10)
(b) 2000 Nonemployee Directors Stock Option Plan (11)
(c) Assignment of Know-How Agreement, dated
June 30, 1989 - (1) (Exhibit 10(g)).
(d) Assignment of Patents - Bipolar Electrosurgical Systems,
June 30, 1989 - (1) (Exhibit 10(h)).
[27]
(e) Assignment of Patents - Binocular
Magnification System, June 30, 1989 -(1)
(Exhibit 10(i)).
(f) Assignment of Malis trade name, dated
June 30, 1989 - (1) (Exhibit 10(j)).
(g) 401(k) and Profit-Sharing Plan - (2) (Exhibit 10(x)).
(h) Promissory Note from Jerry L. Malis to the Company.
(4) (Exhibit 10(k))
(i) Commercial Lease Agreement between GMM
Associates and the Company dated July 1, 1995 (5)
(Exhibit 10(p))
(j) Promissory Note from Jerry L. Malis to the Company
(7) (Exhibit 10(p)).
(k) Distribution Agreement between the Company and
Codman & Shurtleff, Inc., dated December 11,
2000 (9) (Exhibit 10.1)
(l) Addendum to Commercial Lease Agreement between the Company
and GMM Associates dated as of July 1, 2000 (9) (Exhibit 10.2)
(21) Subsidiaries of Registrant
Subsidiaries of Valley Forge Scientific Corp. (6) (Exhibit 21)
(23) Consent of Samuel Klein & Company
- ----------
(1) Previously filed with the Registration Statement
of the Company on Form S-18, Registration No. 33-31008-
NY, and incorporated herein by reference.
(2) Previously filed with the Registration Statement
of the Company on Form S-18, Registration No. 33-35668-
NY, and incorporated herein by reference.
(3) Previously filed with the Company's Form
8-K dated August 31, 1994, and incorporated
herein by reference.
(4) Previously filed with the Company's Form
10-K for the year ended September 30, 1994,
and incorporated herein by reference.
(5) Previously filed with the Company's Form 10-K for
the year ended September 30, 1995, and incorporated
herein by reference.
(6) Previously filed with the Company's Form 10-K for
the year ended September 30, 1997, and incorporated
herein by reference.
(7) Previously filed with the Company's Form 10-K for
the year ended September 30, 1998 and incorporated
herein by reference.
(8) Previously filed with the Company's Form 10-K for
the year ended September 30, 1999 and incorporated
herein by reference.
(9) Previously filed with the Company's Form 10-Q for
the quarter ended December 31, 2000, and incorporated
herein by reference.
(10) Previously filed with the Registration Statement of the
Company on Form S-8 Registration No.333-72296, filed on
October 26, 2001 and incorporated herein by reference
(11) Previously filed with the Registration Statement of the
Company on Form S-8 Registration No.333-72134, filed on
October 24, 2001 and incorporated herein by reference.
(12) Previously filed with the Company's Form 10-K for the
year ended December 31, 2001 and incorporated herein by
reference.
[28]
SIGNATURES
Pursuant to the requirements of the Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized on this 16th day of
December, 2002
VALLEY FORGE SCIENTIFIC CORP.
By: /s/ Jerry L. Malis
Jerry L. Malis, President
Pursuant to the requirements of the Securities Act of 1934, this report
has been signed by the following persons on behalf of the Registrant and in the
capacities and on the dates indicated.
Signature Title Date
/s/ Jerry L. Malis
- --------------- -- Chairman of the Board, December 16, 2002
Jerry L. Malis President (chief executive
officer and principal
financial and accounting officer)
/s/ Louis Uchitel Director December 16, 2002
- ----------------
Louis Uchitel
Leonard I. Malis Director
/s/ Bruce A. Murray Director December 16, 2002
- ------------------
Bruce A. Murray
/s/ Robert H. Dick Director December 16, 2002
==================
Robert H. Dick
CERTIFICATION
I, Jerry L. Malis, certify that:
1. I have reviewed this annual report on Form 10-K of Valley Forge
Scientific Corp;
2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact necessary to make the statements made, in light of
the circumstances under which such statements were made, not misleading with
respect to the period covered by this annual report;
3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:
a) Designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this annual report is being prepared;
b) Evaluated the effectiveness of the registrant's disclosure
controls and procedures as of a date within 90 days prior to the filing date of
this annual report (the "Evaluation Date"); and
c) Presented in this annual report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed,
based on our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent functions):
a) All significant deficiencies in the design or operation of
internal controls which could adversely affect the registrant's ability to
record, process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and
b) Any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's internal
controls; and
6. The registrant's other certifying officers and I have indicated in this
annual report whether there were significant changes in internal controls or in
other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.
/s/ Jerry L. Malis
Dated: December 16, 2002 Jerry L. Malis,
President, Principal Executive
Officer, and Principal Financial Officer
VALLEY FORGE SCIENTIFIC CORP.
For Fiscal Year Ended September 30, 2002
FORM 10-K
Index to Financial Statements and Financial Statement Schedules
Independent Auditor's Report F-2
Balance Sheets - September 30, 2002 and 2001 F-3
Statements of Operations -
Years ended September 30, 2002, 2001 and 2000 F-4
Statements of Stockholders' Equity -
Years ended September 30, 2002, 2001 and 2000 F-5
Statements of Cash Flows -
Years ended September 30, 2002, 2001 and 2000 F-6
Notes to Financial Statements F-7
===============
All other schedules for which provision is made in the applicable accounting
regulations of the Securities and Exchange Commission are not required under the
related instructions or are not applicable, and therefore have been omitted.
[F-1]
INDEPENDENT AUDITOR'S REPORT
The Board of Directors and Stockholders
Valley Forge Scientific Corp. and Subsidiaries
Oaks, Pennsylvania
We have audited the accompanying consolidated balance sheets of Valley Forge
Scientific Corp. and Subsidiaries as of September 30, 2002 and 2001 and the
related consolidated statements of operations, stockholders' equity and cash
flows for each of the three years in the period ended September 30, 2002. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audits to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Valley Forge Scientific Corp.
and Subsidiaries as of September 30, 2002 and 2001, and the results of
operations and cash flows for each of the three years in the period ended
September 30, 2002, in conformity with accounting principles generally accepted
in the United States of America.
/s/Samuel Klein And Company
SAMUEL KLEIN AND COMPANY
Newark, New Jersey
November 27, 2002
F-2
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
September 30,
ASSETS 2002 2001
- ------ ---- ----
Current Assets:
Cash and cash equivalents $ 2,543,898 $ 1,500,622
Accounts receivable, net 337,939 605,150
Inventory 882,832 1,199,536
Prepaid items and other current assets 140,784 107,304
Deferred tax assets 76,293 104,380
----------- -----------
Total Current Assets 3,981,746 3,516,992
Property, Plant and Equipment, Net 136,131 145,800
Goodwill 153,616 153,616
Intangible Assets, Net 294,371 349,360
Other Assets 4,171 5,446
----------- -----------
Total Assets $ 4,570,035 $ 4,171,214
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable and accrued expenses $ 200,972 $ 191,786
Income taxes payable 152,309 91,400
----------- -----------
Total Current Liabilities 353,281 283,186
Deferred Tax Liability 14,357 19,280
----------- -----------
Total Liabilities 367,638 302,466
----------- -----------
Commitments and Contingencies
Stockholders' Equity:
Preferred stock - -
Common stock (no par, 20,000,000 shares
authorized, shares issued and outstanding
at September 30, 2002 - 8,041,312 and at
September 30, 2001 - 8,067,812) 3,701,846 3,748,724
Retained earnings 500,551 120,024
----------- -----------
4,202,397 3,868,748
----------- -----------
Total Liabilities and Stockholders' Equity $ 4,570,035 $ 4,171,214
=========== ===========
- ---------------------
The accompanying notes are an integral part of these financial statements.
F-3
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
For the Years Ended September 30,
2002 2001 2000
---- ---- ----
Net Sales $ 5,021,931 $ 5,263,485 $ 4,397,939
Cost of Sales 2,463,209 2,692,036 2,443,406
----------- ----------- -----------
Gross Profit 2,558,722 2,571,449 1,954,533
----------- ----------- -----------
Other Costs:
Selling, general and administrative 1,503,001 1,652,289 1,646,438
Research and development 360,111 352,773 338,318
Amortization 63,610 80,641 80,594
----------- ----------- -----------
Total Other Costs 1,926,722 2,085,703 2,065,350
----------- ----------- -----------
Income (Loss) from Operations 632,000 485,746 (110,817)
Other Income (Expense), Net 23,111 39,428 38,243
----------- ----------- -----------
Income (Loss) before Income Taxes 655,111 525,174 (72,574)
Provision for (Benefit of) Income Taxes 274,584 194,953 (18,262)
----------- ----------- -----------
Net Income (Loss) $ 380,527 $ 330,221 $ (54,312)
=========== =========== ===========
Income (Loss) per Share:
Basic income (loss) per common share $ 0.05 $ 0.04 $ (0.01)
=========== =========== ===========
Diluted income (loss) per common share $ 0.05 $ 0.04 $ (0.01)
=========== =========== ===========
Basic weighted average common shares
outstanding 8,067,286 8,081,890 8,193,034
Diluted weighted average common shares
outstanding 8,154,570 8,152,946 8,193,034
- --------------------
The accompanying notes are an integral part of these financial statements.
F-4
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE YEARS ENDED SEPTEMBER 30, 2002, 2001 AND 2000
Common Stock
No Par Value
--------------------
Number Common Retained Total
of Stock Earnings Stockholders'
Shares Amount (Deficit) Equity
------ ------ --------- ------------
Balances, October 1, 1999 8,217,309 $ 4,006,825 $ (155,885) $ 3,850,940
Purchases and Retirement of
Common Shares (65,447) (147,395) - (147,395)
Net Loss for the Year Ended
September 30, 2000 - - (54,312) (54,312)
--------- ----------- ---------- -----------
Balances, September 30, 2000 8,151,862 3,859,430 (210,197) 3,649,233
Purchases and Retirement of
Common Shares (84,050) (110,706) - (110,706)
Net Income for the Year Ended
September 30, 2001 - - 330,221 330,221
--------- ----------- ---------- -----------
Balances, September 30, 2001 8,067,812 3,748,724 120,024 3,868,748
Purchases and Retirement of
Common Shares (26,500) (46,878) - (46,878)
Net Income for the Year Ended
September 30, 2002 - - 380,527 380,527
--------- ----------- ---------- -----------
Balances, September 30, 2002 8,041,312 $ 3,701,846 $ 500,551 $ 4,202,397
========= =========== ========== ===========
- --------------------
The accompanying notes are an integral part of these financial statements.
F-5
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Years Ended September 30,
2002 2001 2000
---- ---- ----
Cash Flows from Operating Activities:
Net income (loss) $ 380,527 $ 330,221 $ (54,312)
Adjustments to reconcile net income (loss) to net
cash provided by (used in) operating activities:
Depreciation and amortization 84,784 118,601 118,980
Writedown of property, plant and equipment 5,300 - -
Allowance for loans and advances to employee - 48,384 -
Reduction of allowance for loans and advances
to employee (47,790) - -
Interest accrued on loans and advances to
employees and related parties (2,810) (4,737) (3,732)
Changes in assets and liabilities, net of effect from:
(Increase) decrease in accounts receivable, net 267,211 22,105 (86,799)
(Increase) decrease in inventory 316,704 (21,689) (7,338)
(Increase) decrease in deferred tax assets 28,087 104,934 (16,279)
(Increase) decrease in other assets 1,275 2,200 (2,834)
Increase in prepaid items and other current
assets (38,705) (20,649) (13)
Increase in accounts payable and accrued
expenses and income taxes payable 70,095 101,001 15,567
Increase (decrease) in deferred tax liability (4,923) (1,381) 3,776
----------- ----------- -----------
Net cash provided by (used in) operating
activities 1,059,755 678,990 (32,984)
----------- ----------- -----------
Cash Flows from Investing Activities:
Proceeds from repayment of employee loans 57,261 6,150 3,575
Loans and advances to employees (1,436) (22,410) (14,940)
Acquisition of intangible assets (8,621) (1,416) -
Purchases of property, plant and equipment (16,805) (15,226) (1,478)
----------- ----------- -----------
Net cash provided by (used in) investing
activities 30,399 (32,902) (12,843)
----------- ----------- -----------
Cash Flows from Financing Activities:
Repurchase of common stock (46,878) (110,706) (147,395)
----------- ----------- -----------
Net cash used in financing activities (46,878) (110,706) (147,395)
----------- ----------- -----------
Net Increase (Decrease) in Cash and Cash
Equivalents 1,043,276 535,382 (193,222)
Cash and Cash Equivalents, beginning of year 1,500,622 965,240 1,158,462
----------- ----------- -----------
Cash and Cash Equivalents, end of year $ 2,543,898 $ 1,500,622 $ 965,240
=========== =========== ===========
Supplemental Disclosures of Cash Flow Information:
Cash paid during the year for:
Interest $ - $ - $ -
=========== =========== ===========
Income taxes $ 186,960 $ 1,500 $ 2,500
=========== =========== ===========
- -------------------
The accompanying notes are an integral part of these financial statements.
F-6
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The Company
- ----------
Valley Forge Scientific Corp. ("VFSC") was incorporated on March 27, 1980 in the
Commonwealth of Pennsylvania and is engaged in the business of developing,
manufacturing and selling medical devices and products. On August 18, 1994,
VFSC formed a wholly-owned subsidiary, Diversified Electronics Company, Inc.
("DEC"), a Pennsylvania corporation, in order to continue the operations of
Diversified Electronic Corporation, a company which was merged with and into
VFSC on August 31, 1994. In January 1993, VFSC formed a wholly-owned
subsidiary, Valley Consumer Products, Inc. ("VCP") to market specific product
lines. During each of the years reported with these financial statements VCP
has been inactive. Collectively, VFSC, DEC and VCP are referred to herein as
the "Company".
Principles of Consolidation and Basis of Presentation
- -----------------------------------------------------
The accompanying financial statements consolidate the accounts of the parent
company and its wholly-owned subsidiaries. All significant intercompany
accounts and transactions have been eliminated in consolidation.
Use of Management's Estimates
- -----------------------------
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.
Cash and Cash Equivalents
- -------------------------
The Company considers cash equivalents to be all highly liquid investments with
original maturities of three months or less. Substantially all cash and cash
equivalents are held in one major financial institution.
Segment Information
- -------------------
The Company has one operating segment that comprises its bipolar electrical
generators and instrumentation products. The Company's business is conducted
entirely in the United States. Significant customers are discussed elsewhere in
Note 11.
Fair Value of Financial Instruments
- -----------------------------------
Carrying amounts of certain of the Company's financial instruments, including
cash and cash equivalents, trade receivables, accounts payable and other accrued
liabilities approximate fair value because of their short maturities.
Revenue Recognition
- ------------------
The Company sells its products to national and international distributors which
include an affiliate of a major medical products companies. A significant part
of the Company's sales are made pursuant to distribution agreements with these
Companies which typically provide exclusive distribution rights of specified
products in a defined medical field, within a territory or territories, during
the term of such agreements. The agreements typically include a price list for
the specified product or products which is fixed for a period of time, after
which these prices are subject to adjustment by the Company due to changes in
manufacturing cost or technological improvements to the products.
F-7
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
1. THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Revenue Recognition (Continued)
- -------------------
Product revenue is recognized when the product has been shipped which is when
the title and risk of loss has been transferred to the customer. Service
revenue substantially relates to repairs of product and is recognized when the
service has been completed. Revenues from license and royalty fees are recorded
when earned.
The Company reduces revenue for customer returns and allowances. In addition,
the Company accrues for warranty cost and other allowances based on its
experience and reflects these accruals in cost of sales or administrative
expense as applicable.
The Company adopted Staff Accounting Bulletin No. 101 "Revenue Recognition in
Financial Statements" (SAB 101) in the first quarter of fiscal year ended
September 30, 2001. The adoption of SAB 101 did not have a material impact on
the Company's financial position or results of operations.
Inventory
- ---------
Inventory is stated at the lower of cost, determined by the moving average cost
method, or market. The Company provides inventory allowances based on
slow-moving and obsolete inventories.
Property, Plant and Equipment
- -----------------------------
Property, plant and equipment are recorded at cost. Depreciation is computed by
the straight-line method over the estimated useful lives of the assets, which
vary from three to thirty-nine years. Leasehold improvements are being
amortized over the related lease term or estimated useful lives, whichever is
shorter.
Upon retirement or other disposition of these assets, the cost and related
accumulated depreciation are removed from the accounts and the gains or losses
are reflected in the results of operations. Routine maintenance and repairs are
charged to expense as incurred.
Intangible Assets and Goodwill
- ------------------------------
Intangible assets, consisting of patents, licensing agreements, proprietary
know-how, logos and cost of acquisition are amortized to operations under the
straight-line method over their estimated useful lives or statutory lives,
whichever is shorter. Acquisition costs have been capitalized and are being
amortized over 5 years. All other intangible assets, except for goodwill, are
being amortized over periods ranging from 15 years to 17 years.
As of October 1, 2001, the Company early-adopted Statement of Financial
Accounting Standards No. 142, "Goodwill and Other Intangible Assets" (SFAS
142), which addresses the financial accounting and reporting standards for
goodwill and other intangible assets subsequent to their acquisition. This
accounting standard requires that goodwill no longer be amortized, and instead,
be tested for impairment on a periodic basis. Pursuant to adoption of this
accounting standard, a transitional impairment test was completed, and no
impairment was identified.
In accordance with SFAS 142, the Company discontinued the amortization of
goodwill effective October 1, 2001.
F-8
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
1. THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Intangible Assets and Goodwill (Continued)
- ------------------------------
A reconciliation of previously reported net income and earnings per share to the
amounts adjusted for the exclusion of goodwill amortization, net of the related
income tax effect, is shown in Note 5.
Impairment of Long-Lived Assets
- -------------------------------
Long-lived assets and certain identifiable intangible assets to be held and used
are reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of such assets may not be recoverable. Determination
of recoverability is based on an estimate of undiscounted future cash flows
resulting from the use of the asset and its eventual disposition. Measurement
of an impairment loss for long-lived assets and certain identifiable intangible
assets that management expects to hold and use is based on the fair value of the
asset. Long-lived assets and certain identifiable intangible assets to be
disposed of are reported at the lower of carrying amount or fair value less
costs to sell.
Research and Development
- ------------------------
Costs associated with development of new products are charged to operations as
incurred.
Advertising Costs
- -----------------
Advertising expenditures relating to the advertising and marketing of the
Company's products and services are expensed in the period the advertising costs
are incurred. Substantially all cost of such product marketing and advertising
has been borne by the Company's major distributors.
Income Taxes
- ------------
Tax provisions and credits are recorded at enacted tax rates for taxable items
included in the consolidated statements of operations regardless of the period
for which such items are reported for tax purposes. Deferred tax assets and
liabilities are determined based on the differences between the financial
statement and tax bases of assets and liabilities using enacted tax rates in
effect for the year in which the differences are expected to reverse. Deferred
tax assets are reduced by a valuation allowance when the determination can be
made that it is more likely than not that some portion or all of the related tax
assets will not be realized.
Comprehensive Income
- --------------------
The Company reports components of comprehensive income under the requirements of
Statement of Financial Accounting Standards No. 130, "Reporting Comprehensive
Income" (SFAS 130). This statement establishes rules for the reporting of
comprehensive income and its components which require that certain items such as
foreign currency translation adjustments, unrealized gains and losses on certain
investments in debt and equity securities, minimum pension liability adjustments
and unearned compensation expense related to stock issuances to employees be
presented as separate components of stockholders' equity.
F-9
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
1. THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Earnings (Loss) per Share
- -------------------------
The Company computes earnings or loss per share in accordance with Statement of
Financial Accounting Standards No. 128, "Earnings Per Share" (SFAS 128). Basic
earnings per share is computed by dividing income available to common
stockholders by the weighted average number of common shares outstanding.
Diluted earnings per share reflects the potential dilution that could occur if
securities or other agreements to issue common stock were exercised or converted
into common stock. Diluted earnings per share is computed based upon the
weighted average number of common shares and dilutive common equivalent shares
outstanding, which include convertible debentures, stock options and warrants.
Accounting for Stock-Based Compensation
- ---------------------------------------
Stock compensation plans for employees are accounted for using the intrinsic
value method of Accounting Principles Board Opinion No. 25 (APB 25). Under APB
25, compensation expense is determined on the measurement date, that is, the
first date on which both the number of shares the employee is entitled to
receive and the exercise price, if any, are known. Compensation expense, if
any, is the excess of the market price of the stock over the exercise price on
the measurement date. The amount of compensation expense, if any, is charged to
operations over the vesting period. The Company utilizes the Black-Scholes
model to value stock options for pro forma presentation of income and per share
data as if the fair value-based accounting method in Statement of Financial
Accounting Standards No. 123, "Accounting for Stock-Based Compensation" (SFAS
123), had been used to account for stock-based compensation.
In accounting for options granted to persons other than employees (as defined
under SFAS 123), the provisions under SFAS 123 were applied. As required by
SFAS 123, the fair value of these options was estimated at the grant date using
the Black-Scholes option pricing model.
Recent Accounting Pronouncements
- --------------------------------
In June 2001, the Financial Accounting Standards Board (FASB) issued Statement
of Financial Accounting Standards No. 143, "Accounting for Asset Retirement
Obligations" (SFAS 143). SFAS 143 addresses financial reporting for obligations
associated with the retirement of tangible long-lived assets and the associated
retirement costs. The adoption of SFAS 143 is effective for fiscal years
beginning after June 15, 2002. The Company does not expect the adoption of SFAS
143 to have a significant impact on the Company's future financial position or
results of operations.
In August 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or
Disposal of Long-Lived Assets. SFAS 144 supersedes SFAS 121, "Accounting for
the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed
of". The primary objectives of SFAS 144 are to develop one accounting model
based on the framework established in SFAS 144 for long-lived assets to be
disposed of by sale, and to address significant implementation issues. The
Company will adopt SFAS 144 for its fiscal year beginning October 1, 2002. The
Company does not expect the adoption of SFAS 144 to have a significant impact on
its future financial position or results of operations.
F-10
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
1. THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Recent Accounting Pronouncements (Continued)
- --------------------------------
In April 2002, the FASB issued SFAS No. 145, "Rescission of FASB Statements No.
4, 44 and 64, Amendment of FASB Statement No. 13 and Technical Corrections."
SFAS 145 updates, clarifies and simplifies certain accounting pronouncements.
The adoption of SFAS 145 is effective in large part for transactions occurring
after May 15, 2002. SFAS 145 had no impact on the Company's financial position
or results of operations in the year ended September 30, 2002 and the Company
does not expect the adoption of SFAS 145 to have an impact on its future
financial position or results of operations.
In June 2002, the FASB issued SFAS No. 146, "Accounting for Costs Associated
with Exit or Disposal Activities". SFAS 146 addresses financial accounting and
reporting for costs associated with exit or disposal activities and nullifies
Emerging Issues Task Force Issue No. 94-3. The adoption of SFAS 146 is
effective for exit or disposal activities initiated after December 31, 2002.
The Company does not expect the adoption of SFAS 146 to have a significant
impact on its future financial position or results of operations.
Reclassifications
- -----------------
Certain reclassifications have been made to the prior year balances to conform
to the current year's presentation.
2. ACCOUNTS RECEIVABLE
The Company provides an allowance for doubtful accounts equal to the estimated
uncollectible amounts. The Company's estimate is based on historical collection
experience and a review of the current status of trade accounts receivable. It
is reasonably possible that the Company's estimate of the allowance for doubtful
accounts will change. Accounts receivable consists of the following:
September 30,
2002 2001
---- ----
Accounts receivable $ 385,483 $ 637,066
Less Allowance 47,544 31,916
--------- ---------
$ 337,939 $ 605,150
========= =========
The Company provided for estimated doubtful accounts through charges to selling,
general and administrative expenses for $50,003, $26,316 and $45,635 for the
years ended September 30, 2002, 2001 and 2000, respectively, and wrote-off
$34,375, $19,400 and $29,183, respectively, against this allowance for these
periods.
F-11
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
3. INVENTORY
The Company provides an allowance for slow moving and potentially obsolete
inventories. Inventory consists of the following:
September 30,
2002 2001
---- ----
Finished goods $ 87,748 $ 78,083
Work-in-process 368,068 464,533
Materials and parts 515,586 733,798
Less: Allowance for slow moving
and obsolete inventory 88,570 76,878
--------- -----------
$ 882,832 $ 1,199,536
========= ===========
The Company provided for obsolete and slow moving inventory through charges to
cost of sales for $52,875, $22,500 and $30,000 in the years ended September 30,
2002, 2001 and 2000, respectively, and wrote off $41,183, $110,621 and $ - 0 -,
respectively, against this allowance for these periods.
4. PROPERTY, PLANT AND EQUIPMENT
Useful Life September 30,
(Years) 2002 2001
----- ---- ----
Land - $ 11,953 $ 11,953
Buildings and improvements 15-39 94,832 91,917
Furniture and fixtures 5- 7 17,953 16,669
Laboratory equipment 5-10 357,544 360,644
Office equipment 5 146,984 136,578
Leasehold improvements 3- 5 9,413 9,413
--------- ---------
638,679 627,174
Less: Accumulated depreciation
and amortization 502,548 481,374
--------- ---------
$ 136,131 $ 145,800
========= =========
Depreciation is reflected in both cost of sales and selling, general and
administrative expenses. Total depreciation for the years ended September 30,
2002, 2001 and 2000 was $21,174, $37,961 and $38,386, respectively.
During the year, the Company entered into an agreement to sell the building in
which it conducts its manufacturing operations for an amount of $117,500. The
agreement was subject to certain contingencies. This agreement was cancelled by
mutual consent of the parties later in the fiscal year.
F-12
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
5. GOODWILL
As indicated in Note 1 - Significant Accounting Policies, pursuant to
SFAS 142, the Company discontinued the amortization of goodwill effective
October 1, 2001.
As required by SFAS 142, a reconciliation of previously reported net income and
earnings per share to the amounts adjusted for the exclusion of goodwill
amortization, net of related income tax effect follows:
For the Years Ended
September 30,
2002 2001 2000
----- ---- ----
Reported net income (loss) $ 380,527 $ 330,221 $ (54,312)
Add: Goodwill amortization,
net of tax - 17,556 17,556
----------- ----------- -----------
Adjusted net income (loss) $ 380,527 $ 347,777 $ (36,756)
=========== =========== ===========
Basic and diluted net
income per share:
Reported basic and diluted net
income (loss) per share $ 0.05 $ 0.04 $ (0.01)
Add: Goodwill amortization,
net of tax - - -
----------- ----------- -----------
Adjusted basic and diluted
net income (loss) per share $ 0.05 $ 0.04 $ (0.01)
=========== =========== ===========
6. INTANGIBLE ASSETS
Intangible assets consist of the following:
Useful Life September 30,
(Years) 2002 2001
----- ---- ----
Patents/trademarks/logos, licensing
agreements 17 $ 569,009 $ 560,388
Proprietary know-how 15 452,354 452,354
Acquisition costs 5 55,969 55,969
----------- -----------
1,077,332 1,068,711
Less: Accumulated amortization 782,961 719,351
----------- -----------
$ 294,371 $ 349,360
=========== ===========
Total amortization for the years ended September 30, 2002, 2001 and 2000 was
$63,610, $63,084 and $63,038, respectively. Amortization for the years ended
September 30, 2003, 2004, 2005, 2006 and 2007 is estimated to be $64,042,
$64,042, $48,173, $30,157 and $30,157, respectively.
F-13
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
7. OTHER RECEIVABLES
The Company from time to time has made advances and loans to certain employees.
These loans and advances are unsecured, payable on demand and have stated
interest rates ranging from 4.57% to 8.20%, the then current "Applicable Federal
Rate" as set forth under the Internal Revenue Code as of each date of advance or
loan. During the fourth quarter of fiscal year ending September 30, 2001, as a
result of the termination subsequent to year end of an employee from whom
approximately $49,500 remained outstanding, the Company recorded an allowance of
approximately $48,400 against the amount owed by this individual. The
outstanding balance was received in the first quarter of the current fiscal
year.
As of September 30, 2002 and 2001, the balance of these loans net of the
allowances was approximately $ - and $6,700, respectively, and is reflected on
the balance sheet under the caption "prepaid expenses and other current assets."
8. RELATED PARTY TRANSACTIONS
Loans Receivable
- ----------------
On July 6, 1998, Jerry L. Malis, a principal shareholder, director and officer
of the Company, borrowed $15,015 from the Company. The note is payable on
demand and has a stated rate of interest of 5.42%, the then current "Applicable
Federal Rate" as set forth under the Internal Revenue Code. The Company has
additional loans due from Jerry L. Malis payable on demand with similar interest
terms as stated above ranging from 4.83% to 6.97%. The collective loans, which
total $53,597 as of September 30, 2002, are partially secured by 5,833 shares of
common stock of the Company. As of September 30, 2002 the pledged stock had a
value of approximately $9,700.
The balance of these loans is reflected on the balance sheet under the caption
"prepaid expenses and other current assets" and as of September 30, 2002 and
2001, was $53,597 and $50,819, respectively, including accrued interest of
$15,762 and $12,984, respectively.
Consulting Services
- -------------------
During 2002, 2001 and 2000 the Company engaged R.H. Dick and Company, Inc., a
corporation owned by Robert H. Dick, a director of the Company, to provide
certain investment banking and consulting services. For the years ended
September 30, 2002, 2001 and 2000 the Company incurred consulting fees from
these services in an amount totaling $10,000, $15,000 and $5,594, respectively.
As of September 30, 2002 and 2001, the Company owed R.H. Dick and Company $2,500
and $5,187, respectively. The liability is reflected on the balance sheet under
the caption "accounts payable and accrued expenses".
9. LINE OF CREDIT
The Company has a line of credit of $1,000,000 with First Union National Bank
which calls for interest to be charged on any loans under this line equal to the
bank's national commercial rate. The line is unsecured and any borrowing under
the line would be payable on demand, require monthly interest payments on any
unpaid principal and a reduction of any loan balance to zero for a minimum of
thirty consecutive days during each twelve month period. In addition, the loan
covenant calls for a minimum tangible net worth of no less than $3,000,000
during the term of the extended line of credit. At September 30, 2002 and 2001,
there were no outstanding balances under this line.
F-14
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
10. COMMITMENTS AND CONTINGENCIES
Litigation
- ----------
The Company is subject from time to time to litigation arising from the normal
course of business. In management's opinion, any such contingencies would be
covered under its existing insurance policies or would not materially affect the
Company's financial position or results of operations.
On July 25, 2001 the Company was named as a defendant in a lawsuit filed in the
United States District Court for the Eastern District of Pennsylvania by a
former employee alleging gender discrimination and sexual harassment. On March
2, 2002 the Company, without admitting any liability, entered into a settlement
agreement and pursuant to this agreement, paid the plaintiff $37,000, an amount
which was net of certain amounts due from this party. This payment is reflected
in other costs under selling, general and administrative expenses for the year
ended September 30, 2002.
On September 19, 2002, the Company was served with a complaint that was filed in
the Superior Court of the State of Arizona, County of Maricopa, entitled Jeffrey
Turner and Cathryn Turner et al v. Phoenix Children's Hospital, Inc., et al, (CV
2002-010791) in which the Company was named as one of the defendants. The
plaintiffs seek an unspecified amount of damages for alleged injuries sustained
in a surgery that took place in June 2000. The Company's product liability
insurance carrier is providing the Company's defense in this matter. This
insurance coverage has a $10,000 deductible that applies to attorney fees and
damages which has been provided for in other costs under selling, general and
administrative expense for the year ended September 30, 2002. In an answer that
was filed on November 26, 2002, the Company denied any liability. The Company
believes the claim is without merit and will vigorously defend itself in this
action.
Regulatory Compliance
- ---------------------
The Company is subject to regulatory requirements throughout the world. In the
normal course of business, these regulatory agencies may require companies in
the medical industry to change their products or operating procedures, which
could affect the Company. The Company regularly incurs expenses to comply with
these regulations and may be required to incur additional expenses. Management
is not able to estimate any additional expenditures outside the normal course of
operations which will be incurred by the Company in future periods in order to
comply with these regulations.
Employment Agreements
- ---------------------
On September 30, 1999, the Company entered into one year employment agreements
with Messrs. Malis and Gilloway effective October 1, 1999. Under the terms, the
agreements provided for an annual base salary of $198,950 for Jerry L. Malis and
$90,000 for Thomas J. Gilloway. Although the agreements for Messrs. Malis and
Gilloway have not been further extended, the Company continued to provide
compensation to them at the annual rate of $198,950 and $90,000, respectively.
The base salaries for the years ended September 30, 2002, 2001 and 2000 were
approximately $199,000, $199,000 and $199,000 for Jerry L. Malis and
approximately $ -, $69,000 and $91,000 for Thomas J. Gilloway, respectively. Mr.
Gilloway passed away on February 18, 2001 and the Company continued to pay his
salary to his spouse until June 29, 2001. The amount reflected as paid to him
for the year ended September 30, 2001 includes the amount paid to his spouse
subsequent to his death.
F-15
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
10. COMMITMENTS AND CONTINGENCIES (Continued)
Employment Agreements (Continued)
- ---------------------
Subsequent to September 30, 2002, the Compensation Committee of the Board of
Directors approved a $25,000 cash bonus to Mr. Malis for services rendered
during the year ended September 30, 2002. In addition, the Compensation
Committee approved an increase to Mr. Malis's annual base salary to $220,000
effective October 1, 2002.
401(k) Profit Sharing Plans
- ---------------------------
The Company's 401(k) Plan and Profit Sharing Plan cover full-time employees who
have attained the age of 21 and have completed at least one year of service with
the Company. Under the 401(k) Plan, an employee may contribute an amount up to
25% of his compensation to the Plan on a pretax basis not to exceed the current
Federal limitation of $11,000 per year (as adjusted for cost of living
increases). Amounts contributed to the 401(k) Plan are nonforfeitable.
Under the Profit Sharing Plan, a member in the plan participates in the
Company's contributions to the Plan as of December 31 in any year, with
allocations to individual accounts based on annual compensation. An employee
does not fully vest in the plan until completion of three years of employment.
The Board of Directors determines the Company's contributions to the plan on a
discretionary basis. The Company has not made any contributions to date.
Stock Option Plans
- ------------------
On July 6, 1988, the Company adopted a Nonqualified Employee Stock Option Plan
(the 1988 "Plan") pursuant to which 500,000 shares of Common Stock have been
reserved for issuance to employees, officers, directors or consultants of the
Company. Options granted pursuant to this plan were nontransferable and expired
if not exercised after ten years from the date of grant or for such lesser term
as approved by the Board of Directors. Options may be granted in such amounts
and at such prices as determined by the Board of Directors, but the price per
share shall not be less than the fair market value of the Company's Common Stock
as of the date of grant.
On January 16, 2001, pursuant to the adoption of the 2001 Stock Plan (the "2001
Plan"), the 1988 plan was terminated. As of the date the plan was terminated, a
total of 404,800 options had been granted and were outstanding.
On December 12, 2000, the Company adopted a Non-employee Directors Stock Option
Plan ("Directors Plan") pursuant to which 150,000 shares of Common Stock have
been reserved for issuance to non-employee directors of the Company. The
Directors Plan was approved by the Company's stockholders on March 14, 2001.
Shares issued pursuant to options granted under this plan may be issued from
shares held in the Company's treasury or from authorized and unissued shares.
Under this plan, each Director, on an annual basis, shall be automatically
granted 10,000 options upon the first business day after being elected a
director. The options are immediately vested on the date of grant.
Discretionary options granted pursuant to this plan shall be determined by the
Board of Directors or a duly appointed stock option committee (the "Committee").
Options granted pursuant to this plan shall be nonqualified stock options as
defined in Section 422 of the Internal Revenue Code, will be nontransferable and
expire if not exercised after ten years from the date of grant or for such
lesser term as approved by the Committee. All options shall be issued at a
price per share equal to the fair market value of the Company's Common Stock as
of the date of grant.
F-16
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
10. COMMITMENTS AND CONTINGENCIES (Continued)
Stock Option Plans (Continued)
- ------------------
On January 16, 2001, the Company adopted the 2001 Stock Plan (the "2001 Plan")
pursuant to which 345,000 shares of Common Stock have been reserved for issuance
to employees, officers and consultants of the Company. The 2001 plan was
approved by the Company's stockholders on March 14, 2001. Shares issued
pursuant to this plan may be issued from shares held in the Company's treasury
or from authorized and unissued shares. Options granted pursuant to this plan
are generally nontransferable, except in the event of a participant's death, in
which case the options shall be transferable to the participant's designated
beneficiary or as permitted by law. The options shall expire if not exercised
after ten years from the date of grant or for such lesser term as approved by
the Board of Directors or a duly appointed committee. Options issued to
employees who are then later terminated for cause generally are immediately
forfeited. Options may be granted in such amounts and at such prices as
determined by the Board of Directors or the duly appointed committee, but the
price per share shall not be less than the fair market value of the Company's
Common Stock as of the date of grant in the case of an incentive stock option
and not less than 85% of the fair market value of the Company's Common Stock as
of the date of grant in the case of a non-qualified stock option, as defined in
section 422 of the Internal Revenue Code.
As referred to in Note 1, the Company has adopted the disclosure provisions of
SFAS 123, "Accounting for Stock Based Compensation". As permitted under this
statement, the Company retained its current method of accounting for stock
compensation in accordance with APB 25.
Following is a summary of the Company's various stock option plans:
Weighted
Average
Range of Weighted Remaining
Exercise Average Contractual
Prices Exercise Life
Shares Per Share Price (Years)
------ --------- ----- -----
Options outstanding at
October 1, 1999 392,675 $1.56 - $5.13 $ 2.56 3.72
Granted - - - -
Exercised - - - -
Surrendered,
forfeited or expired (104,600) 1.56 - 5.13 1.66 -
------- ------------ -------
Options outstanding at
September 30, 2000 288,075 1.94 - 4.25 2.88 3.68
Granted 347,000 1.13 - 2.75 2.01 9.38
Exercised - - - -
Surrendered,
forfeited or expired (152,000) 1.94 - 3.63 2.76 1.92
------- ------------ -------
Options outstanding at
September 30, 2001 483,075 1.13 - 4.25 2.29 7.39
Granted 47,500 1.85 - 2.75 2.42 9.64
Exercised - - - -
Surrendered,
forfeited or expired (12,725) 1.13 - 4.25 2.55 5.38
------- ------------ --------
Options outstanding at
September 30, 2002 517,850 $1.13 - 4.25 $ 2.30 6.31
======= ============= ========
F-17
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
10. COMMITMENTS AND CONTINGENCIES (Continued)
Stock Option Plans (Continued)
- ------------------
As of September 30, 2002, options to purchase 345,840 shares are exercisable at
prices ranging from $1.13 to $4.25 which correspond to a weighted average
exercise price of $2.56 and a weighted average remaining contractual life of
7.06 years.
Pro forma information regarding net income and earnings per share is required by
SFAS 123 and has been determined as if the Company had accounted for the
employee stock options under the fair value method of that statement. The fair
value for options granted during the years ended September 30, 2002, 2001 and
2000 was estimated at each date of grant. The fair value of these options was
estimated using a Black-Scholes option valuation model with the following range
of weighted average assumptions:
For the Years Ended
September 30,
2002 2001 2000
---- ---- ----
Risk-free interest
(based on U.S. Government
strip bonds on the date
of grant with maturities
approximating the expected
option term) 3.84% - 5.13% 4.86% - 5.29% -
Dividend yields 0% 0% -
Volatility factors of the
expected market price of
the Company's Common Stock
(based on historical data) 165.1% - 169.7% 90.0% - 96.0% -
Expected life of options 10 Years 10 Years -
The weighted average fair value of options granted during the years ended
September 30, 2002, 2001 and 2000 were as follows:
2002 2001 2000
---- ---- ----
Stock Prices Equal to Exercise Price $2.40 $1.77 $ -
Stock Prices in Excess of Exercise Price $ - $ - $ -
Stock Prices Less than Exercise Price $ - $2.10 $ -
F-18
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
10. COMMITMENTS AND CONTINGENCIES (Continued)
Stock Option Plans (Continued)
- ------------------
The Black-Scholes option valuation model was developed for use in estimating the
fair value of traded options which have no vesting restrictions and are fully
transferable. In addition, option valuation models require the input of highly
subjective assumptions including the expected stock price volatility. Because
the Company's stock options have characteristics significantly different from
those of traded options, and because changes in subjective input assumptions can
materially affect the fair value estimated, in management's opinion, the
existing models do not necessarily provide a reliable single measure of the fair
value of its stock options. In management's opinion existing stock option
valuation models do not provide a reliable single measure of the fair value of
employee stock options that have vesting provisions and are not transferable.
In addition, option pricing models require the input of highly subjective
assumptions, including expected stock price volatility.
For purposes of pro forma disclosures, the estimated fair value of the options
is amortized to expense over the options' vesting period. In accordance with
SFAS 123, only stock options granted after September 30, 1995 have been included
for the Company's pro forma information as follows:
For the Years Ended
September 30,
2002 2001 2000
---- ---- ----
Additional compensation
expense, net of tax effect $ 89,333 $ 56,328 $ -
Pro forma net income (loss) $ 291,194 $ 273,893 $ (54,312)
Pro forma income (loss) per share:
Basic $ 0.04 $ 0.03 $ (0.01)
Diluted $ 0.04 $ 0.03 $ (0.01)
Operating Leases
- ----------------
The Company leases approximately 4,200 square feet of office and warehouse space
in an office building in Oaks, Pennsylvania, from GMM Associates, a Pennsylvania
general partnership, whose partners are Jerry L. Malis, Thomas J. Gilloway
(deceased as of February 18, 2001) and Leonard I. Malis, principal shareholders,
directors and/or officers of the Company. The lease which commenced on July 1,
1995 for a term of five years provided for a monthly base rent of $4,716 (with
increases based on increases in the consumer price index) which include costs
associated with real estate taxes, maintenance and utilities. During December
2000 the lease was extended for an additional term of five years effective as of
July 1, 2000 and calls for a monthly base rent of $4,643 (with increases on June
30th of each year based on increases in the Producer Price Index). All other
terms remain the same. The related expense for this lease for the years ended
September 30, 2002, 2001 and 2000 was $57,740, $56,115 and $56,376,
respectively. As of September 30, 2002, the Company was current on all rental
obligations due the related party.
The Company has also entered into leases for certain equipment under operating
lease agreements with terms ranging between two and four years.
F-19
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
10. COMMITMENTS AND CONTINGENCIES (Continued)
Operating Leases (Continued)
- ----------------
A schedule of future minimum payments under operating leases is as follows:
Years ending September 30,
Related Other
Party Operating
----- ---------
2003 $ 55,716 $ 25,119
2004 55,716 9,511
2005 41,787 8,152
2006 - 866
--------- ---------
$ 153,219 $ 43,648
========= =========
11. MAJOR CUSTOMERS
For the years ended September 30, 2002, 2001 and 2000, a significant part of the
Company's revenues were derived from one major customer pursuant to a
distribution agreement under which the Company granted the exclusive right to
sell its electrosurgical systems and other products developed by the Company in
the field of neurosurgery. Revenues derived from this customer are
approximately as follows:
Percent of
Total
Revenues Revenues
-------- --------
Year ended September 30, 2002 $ 4,515,000 90%
Year ended September 30, 2001 $ 4,169,000 79%
Year ended September 30, 2000 $ 3,696,000 84%
In addition, for the years ended September 30, 2002, 2001 and 2000, revenue
derived from another customer totaled approximately $347,000, $1,009,000 and
$320,000, respectively, representing approximately 7%, 19% and 7%, respectively
of the Company's total revenues.
At September 30, 2002 and 2001, these two customers accounted for approximately
99% and 98%, respectively, of the Company's accounts receivable.
F-20
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
12. STOCKHOLDERS' EQUITY
Common Stock
- ------------
On August 26, 1999, the Company filed an amended and restated Certificate of
Incorporation increasing the shares of Common Stock the Company is authorized
to issue from 10,000,000 to 20,000,000 shares with no stated par value.
The holders of Common Stock have no preemptive rights and the Common stock has
no redemption, sinking fund or conversion provisions. Each share of Common
Stock is entitled to one vote on any matter submitted to the holders and to
equal rights in the assets of the Company upon liquidation. All of the
outstanding shares of Common Stock are fully paid and nonassessable.
In April 2000, the Board of Directors of the Company approved a stock repurchase
program continuing a prior program whereby the Company may, from time to time,
repurchase on the open market up to 200,000 shares of the Company's Common
Stock. In August 2002, the Board of Directors of the Company voted to terminate
the then existing program and approved a new program for the repurchase of up to
200,000 shares of the Company's Common Stock. During the fiscal years ended
September 30, 2002, 2001 and 2000, the Company repurchased for retirement
26,500, 84,050 and 65,447 shares at an aggregate cost of $46,878, $110,706 and
$147,395, respectively.
Preferred Stock
- ---------------
The Company is authorized to issue 487 shares of preferred stock, $1,000 par
value. The holders of the preferred stock would have no voting rights or
preemptive rights. Upon liquidation of the Company, a $1,000 per share
liquidating dividend must be paid upon each issued and outstanding share of
preferred stock before any liquidating dividend is paid on the Common Stock.
For each of the years ended September 30, 2002, 2001 and 2000, there were no
issued or outstanding preferred shares, and the Company has no intention to
issue any preferred stock in the immediate future.
F-21
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
13. EARNINGS (LOSS) PER SHARE
For the Years Ended
September 30,
2002 2001 2000
---- ---- ----
Basic Income (Loss) Per Share:
Income (loss) available to common
shareholders $ 380,527 $ 330,221 $ (54,312)
=========== =========== ===========
Weighted average shares outstanding 8,067,286 8,081,890 8,193,034
=========== =========== ===========
Basic Income (Loss) Per Share $ 0.05 $ 0.04 $ (0.01)
=========== =========== ===========
Diluted Income (Loss) Per Share:
Income (Loss) available to
common shareholders $ 380,527 $ 330,221 $ (54,312)
=========== =========== ===========
Weighted average shares outstanding 8,067,286 8,081,890 8,193,034
Dilutive shares issuable in connection
with stock plans 87,284 71,056 -
----------- ----------- -----------
Dilutive weighted average common
shares outstanding 8,154,570 8,152,946 8,193,034
=========== ========= =========
Diluted Income (Loss) Per Share $ 0.05 $ 0.04 $ (0.01)
=========== =========== ===========
Options to purchase 517,850, 483,075 and 288,075 shares of common stock were
outstanding at September 30, 2002, 2001 and 2000, respectively, and 70,200,
70,200 and 288,075 of these shares were not included in the computation of
diluted earnings per share in accordance with SFAS 128, as the potential shares
are considered anti-dilutive.
F-22
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
14. PROVISION FOR (BENEFIT OF) INCOME TAXES
Provision for (benefit of) income taxes is as follows:
For the Years Ended
September 30,
2002 2001 2000
---- ---- ----
Current:
Federal $ 204,500 $ 74,100 -
State 40,200 17,300 -
--------- --------- ---------
244,700 91,400 -
--------- --------- ---------
Deferred:
Federal 20,703 93,840 (15,884)
State 9,181 9,713 (2,378)
--------- --------- ---------
29,884 103,553 (18,262)
--------- --------- ---------
$ 274,584 $ 194,953 $ (18,262)
========= ========= =========
The Company's effective tax rate was 41.9%, 37.2% and (25.2)% for the years
ended September 30, 2002, 2001 and 2000, respectively. Reconciliation of income
tax at the statutory rate to the Company's effective rate is as follows:
For the Years Ended
September 30,
2002 2001 2000
---- ---- ----
Computed at the expected
statutory rate 34.0 % 34.0 % (18.1)%
State taxes net of
federal tax benefit 6.6 5.9 (6.1)
Other 1.3 (2.7) (1.0)
---- ---- ----
41.9 % 37.2 % (25.2)%
==== ==== ====
F-23
VALLEY FORCE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
14. PROVISION FOR (BENEFIT OF) INCOME TAXES (Continued)
Certain items of income and expense are recognized in different years for
financial reporting and income tax purposes. Deferred income taxes are provided
in recognition of these temporary differences. The items that give rise to the
deferred income tax assets and deferred income tax liability are as follows:
For the Years Ended
September 30,
2002 2001 2000
---- ---- ----
Deferred Tax Assets:
Difference in capitalization
of inventory cost $ 56,993 $ 54,499 $ 89,600
Difference in reporting bad debts 19,300 32,067 10,148
Federal and State of Pennsylvania
net operating loss carryforward - 14,527 106,005
Tax credits and other current assets - 3,287 8,506
---------- ----------- ----------
Total deferred tax assets 76,293 104,380 214,259
Valuation allowance - - (4,945)
---------- ----------- ----------
Total Deferred Tax Assets $ 76,293 $ 104,380 $ 209,314
========== =========== ==========
Deferred Tax Liability:
Difference in reporting
depreciation and
amortization on
long-term assets $ 14,357 $ 19,280 $ 20,661
---------- ----------- ----------
Total Deferred Tax Liability $ 14,357 $ 19,280 $ 20,661
========== =========== ==========
15. CONCENTRATION OF CREDIT RISK
Financial instruments which potentially subject the Company to concentration of
credit risk consist principally of short-term cash investments and trade
receivables. The Company maintains substantially all of its banking activities
with one bank and cash balances throughout the year generally exceeded the
federally insured limits of the FDIC and SIPC of $100,000. The Company
typically invests cash balances which exceed $100,000 in money market accounts,
money market mutual funds or short-term municipal securities. During a portion
of 2000, the Company also invested in U.S. Treasury Securities. At September
30, 2002 and 2001, the balances the Company held in these securities was
approximately $2,278,000 and $1,500,000, respectively. Management believes that
its customer acceptance, billing and collection policies are adequate to
minimize potential credit risk associated with trade receivables, which are
principally due from two customers.
F-24
VALLEY FORGE SCIENTIFIC CORP. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Continued)
16. QUARTERLY RESULTS (UNAUDITED)
The following table presents selected unaudited quarterly operating results for
the Company's eight quarters ended September 30, 2002 for continuing operations.
The Company believes that all necessary adjustments have been made to present
fairly the related quarterly results.
Fiscal 2002 First Second Third Fourth
Quarter Quarter Quarter Quarter Total
------- ------- ------- ------- -----
Net sales $ 1,262,406 $ 1,457,798 $ 1,148,278 $ 1,153,449 $ 5,021,931
Gross profit 646,066 760,588 602,406 549,662 2,558,722
Operating income 211,776 199,077 153,378 67,769 632,000
Net income 127,473 117,634 90,669 44,751 380,527
Basic and diluted
net income per
common share $ 0.02 $ 0.01 $ 0.01 $ 0.01 $ 0.05
Fiscal 2001
Net sales $ 1,065,106 $ 1,251,804 $ 1,554,642 $ 1,391,933 $ 5,263,485
Gross profit 494,371 669,589 803,963 603,526 2,571,449
Operating income 11,418 137,166 235,236 101,926 485,746
Net income 17,812 83,592 155,530 73,287 330,221
Basic and diluted
net income per
common share $ 0.00 $ 0.01 $ 0.02 $ 0.01 $ 0.04
F-25
EXHIBIT 22
CONSENT OF SAMUEL KLEIN AND COMPANY
INDEPENDENT ACCOUNTANTS
We consent to the incorporation by reference in the registration statements
of Valley Forge Scientific Corp. and its subsidiaries on Form S-8 (File No.
333-63637; 333-72296 and 333-72134) of our report dated November 27, 2002 on our
audits of the financial statements of Valley Forge Scientific Corp. and its
subsidiaries as of September 30, 2002 and 2001, and for each of the three years
in the period ended September 30, 2002, which report is included in this Annual
Report on Form 10-K.
SAMUEL KLEIN AND COMPANY
/s/ SAMUEL KLEIN AND COMPANY
Newark, New Jersey
December 16, 2002